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Summary  
 
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading 
cause of cancer-related mortality worldwide. The high mortality rates have been attributed to 
late diagnosis and limited treatment options available. Sorafenib, a multi- kinase inhibitor, is 
currently the only targeted therapy that has shown survival benefits in advanced HCC 
patients. Several other targeted therapies, which were successful in animal models of HCC 
and in human cancer of head and neck, were met with limited success in HCC patients. Due 
to the unmet medical needs, it is clear that characterization of the mechanisms during 
hepatocarcinogenesis is pivotal in identifying novel treatment targets and diagnostic 
biomarkers. 
 
In an effort to identify novel targets during HCC, previous work from the lab has shown that 
TRIP13, a member of the AAA
+
-ATPase family was significantly upregulated in DEN-
induced HCC in mice and in human HCC. TRIP13 has been described to be an important 
regulator of chromosomal events during meiosis and mitosis. An induced expression of 
TRIP13 has been reported in several cancer entities however its cancer-related role remains 
marginally understood. Interestingly, TRIP13 forms part of the chromosomal instability 
(CIN) gene signature that is commonly seen in tumour cells and has DNA-damage repair 
functions in head and neck carcinoma cells (SSCHN). 
 
Unpublished data from the lab was the first to have confirmed the growth-promoting role of 
TRIP13 in liver, which was unveiled during hepatocyte regeneration and tumourigenesis 
using various mouse models of HCC. Here, we aim to dissect the mechanism through which 
TRIP13 exerts its pro-proliferative effects in HCC and to identify novel signalling pathways 
through which TRIP13 could exert its function. 
 
In this study, we showed that TRIP13 is essential during cell growth and proliferation, 
proliferation was severely impaired by Trip13 knockdown in all mouse and human HCC cells 
lines under investigation. Conversely, the overexpression of Trip13 in non-tumourigenic 
AML12 liver cells stimulated cell proliferation significantly, with upregulated expression of 
oncogenic factors like c-MYC, EGFR and cyclin D1. We identified an unexpected functional 
relevance of the interaction between TRIP13 and SIN3A, which was enriched during a MS 
screen for Trip13 interaction partners previously performed in the lab. SIN3A has been 
commonly described as a transcriptional repressor due to its HDAC-related roles. Strikingly, 
a concomitant depletion of SIN3A reverses the growth defect of TRIP13-depleted HCC cells, 
despite accumulated DNA damages (from TRIP13 depletion) still apparent in these growth-
rescued cells.  This growth rescue was paralleled by a partial restoration of c-MYC 
expression levels, which were significantly depleted during TRIP13-KD alone. We further 
demonstrated that the overexpression of c-MYC was able to rescue the growth defect seen in 
TRIP13-depleted cells.  
 
Taken together, this study is the first to report on an oncogenic, pro-proliferative role of 
TRIP13 in liver cancer using both human HCC cells and mice HCC models. An inhibition of 
c-MYC and its downstream targets might account for the growth arrest and apoptotic cell 
death during TRIP13-depletion. Along with the reported roles of SIN3A as a c-MYC 
antagonist, further work is required to decipher a possible cross talk between TRIP13, SIN3A 
and c-MYC and its functional relevance during hepatocarcinogenesis.       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung Summary 
  
Das hepatozelluläre Karzinom (hepatocellular carcinoma, HCC) ist weltweit die fünft-
häufigste Krebsart aber an zweiter Stelle was die Krebs-assoziierten Mortalität angeht. Für 
die hohe Sterbebrate werden insbesondere die späte Diagnose sowie die limitierten 
Behandlungsoptionen verantwortlich gemacht. Die Behandlung mit Sorafenib, einem 
Multikinase-Inhibitor, stellt zurzeit die einzige gerichtete Therapie dar, bei der ein Benefit 
bezüglich Überleben festgestellt werden konnte. Verschiedene andere Therapieansätze, die in 
HCC-Tiermodellen sowie z.B. beim humanen Kopf-Hals Karzinom erfolgreich eingesetzt 
wurden, zeigten bei HCC-Patienten nur eine sehr eingeschränkte Wirkung. Angesichts dieses 
ungedeckten klinischen Bedarfs ist eine weiterführende Charakterisierung der Mechanismen 
der hepatischen Karzinogenese von entscheidender Bedeutung für die Identifikation neuer 
Zielstrukturen für Therapie sowie von diagnostischen Biomarkern. 
In vorherigen Arbeiten aus unserem Labor zur Identifikation neuer Zielstrukturen bei HCC 
wurde gezeigt, dass Trip13, ein Mitglied aus Proteinfamilie der AAA
+
-ATPasen, signifikant 
hochreguliert war beim hepatozellulären Karzinom im Menschen sowie bei 
Diethylnitrosamin-induziertem Leberkrebs in Mäusen. Trip13 war als wichtiger Regulator 
chromosomaler Prozesse während der Meiose und der Mitose beschrieben worden. Eine 
erhöhte Expression von Trip13 war zuvor in mehreren Krebsarten festgestellt worden, wobei 
die krebsfördernde Wirkung mechanistisch nur ansatzweise aufgeklärt wurde. 
Interessanterweise wurde Trip13 einer häufig in Tumourzellen festgestellten Gensignatur für 
chromosomale Instabilität (chromosomal instability, CIN) zugeordnet, sowie einer DNA-
Reparatur-Funktion beim Kopf-Hals-Karzinom. 
In bisher nicht publizierten Daten aus unserem Labor wurde zum ersten Mal eine 
wachstumfördernde Wirkung von Trip13 in der Leber gezeigt, die sich sowohl bei 
Hepatozyten-Regenerationsprozessen als auch bei der Tumourgenese in verschiedenen 
Mausmodellen von HCC bestätigte. Ziel dieser Arbeit war die Aufklärung der Mechanismen 
durch die Trip13 seine pro-proliferative Wirkung ausübt, sowie die Identifikation von bisher 
unbekannten Signalwegen, die daran beteiligt sein könnten. 
In der vorliegenden Studie konnten wir zeigen, dass Trip13 von zentraler Bedeutung für 
Zellwachstum und Proliferation ist. Trip13-Defizienz reduzierte in erheblichem Maß das 
Zellwachstum bei allen untersuchten humanen und murinen HCC-Zelllinien. Umgekehrt 
führte die Überexpression of Trip13 in nicht-tumourbildenden AML12-Leberzellen zu einer 
signifikanten Erhöhung des Zellwachstums (Proliferation), die mit einer Erhöhung der 
Expression von onkogenen Faktoren wie c-MYC, EGFR und Cyclin D1 einher ging. Darüber 
hinaus konnten wir eine unerwartete funktionale Relevanz der Interaktion zwischen Trip13 
und SIN3A feststellen. Der Interaktionspartner SIN3A war zuvor aus einem im Labor 
durchgeführten Screen nach Trip13-Interaktionsproteinen mittels Massenspektrometrie 
hervorgegangen und als transkriptioneller Korepressor in Komplexen mit Histon-
deacetylasen beschrieben worden. Erstaunlicherweise führte die gleichzeitige Ausschaltung 
von SIN3A zu einer vollständigen Aufhebung des wachstumshemmenden Effekts der Trip13-
Depletion in HCC-Zellen. Die Umkehrung des Wachstumseffekts hatte jedoch keinen 
Einfluss auf die Erhöhung der DNA-Schäden, die wir nach Trip13-Depletion detektieren 
konnten. Diese Aufhebung des Wachstumsdefekts ging mit einer zumindest teilweisen 
Wiederherstellung der c-MYC-Expressionslevel einher, die bei der alleinigen Depletion von 
Trip13 erheblich reduziert waren. Darüber hinaus konnten wir zeigen, dass eine  
 
 
 
 
 
Überexpression von c-MYC in der Lage war, den Wachstumsdefekt nach Trip13-Depletion 
umzukehren. 
Diese Arbeit zeigt zum ersten Mal eine onkogene, pro-proliferative Rolle von Trip13 bei 
Leberkrebs unter Verwendung von humanen und murinen HCC-Zelllinien und HCC-Maus-
Modellen. Die Reduktion von c-MYC und dessen Zielgenen könnte dabei für die 
wachstumshemmende und Apoptose-auslösende Wirkung von Trip13-Depletion 
verantwortlich sein. Unter Berücksichtigung der zuvor berichteten Rolle von SIN3A als 
Inhibitor von c-MYC, sind weiterführende Untersuchungen notwendig um die funktionalen 
Zusammenhänge zwischen Trip13, SIN3A und c-MYC hinsichtlich ihrer Relevanz für die 
Hepatokarzinogenese umfassend zu definieren. 
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1 Introduction 
 
1.1 Hepatocellular carcinoma 
 
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second 
leading cause of Cancer-related mortality [64].  Liver carcinogenesis is a highly complicated 
process, which results from a complex interplay between host genetic factors and 
environmental exposure. HCC arises from a plethora of etiological factors that originates 
with a background in chronic liver diseases (CLDs). Such risk factors for the occurrence of 
HCC include chronic Hepatitis B or C infections (HBV, HCV); excessive alcohol 
consumption, autoimmune Hepatitis and several metabolic diseases including Diabetes 
mellitus, diet-induced fatty liver diseases and obesity [65]. The initiation and progression of 
HCC is thought to be a multistep process, involving the progressive accumulation of genetic 
and epigenetic alterations, undermined from different molecular and cellular events that still 
remains poorly understood [66]. 
 
1.2 Genetic landscape and altered cell signaling driver pathways in 
HCC 
 
The liver is rarely affected by classical germ line mutations that predispose during 
the development of colorectal, breast or ovarian cancer. Instead, the 
transformation/proliferation of hepatocytes are usually associated with several single 
nucleotide polymorphisms (SNPs) [67]. Amongst these polymorphisms, many alter the 
carcinogenic pathways and are related to predisposition to specific risk factors during 
chronic liver diseases. PNPL3 was first identified to be a gene encoding for a lipase that 
mediates triacylglycerol hydrolysis [68]. In this example, there is a strong association 
between the SNP of PNPL3 with fatty liver and alcohol induced chronic liver damage, 
alongside an increased risk of HCC occurrence [69].  
Cirrhosis marks the late stages of chronic liver injury when fibrotic tissues overtakes 
the function of hepatocytes, as these cells are forced to chronically alternate between 
necrosis and regeneration and eventually senesces. Cirrhosis paves the way during which 
preneoplastic lesions eventually gives way to malignant transformation in a well defined 
sequence as shown in Fig. 1.1. Damaged cells possibly hepatocytes undergoes initial insults 
to form a low-grade dysplastic nodules (LGDN) which then switches to a high-grade 
dysplastic nodules (HGDN) [66]. Subsequently, early HCC cells are further transformed to 
become highly proliferative and invasive cells in advanced HCC. 
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1.3 Signaling pathways altered in HCC 
 
It has been predicted that the genome from each HCC tumour cell is uniquely 
complex and harbors between 35-80 somatic gene mutations. An overview of the recent 
whole-exome sequencing studies has identified the following 6 signaling pathways to be 
recurrently altered in HCC [66]. These are namely pathways regulating Telomerase 
maintenance; WNT/β-catenin; p-53 cell cycle regulation, epigenetic modifiers, oxidative 
stress and the PI3K/AKT/mTOR, MAPK kinases and are briefly discussed below: 
 
Telomeres are short DNA repeats that are located in chromosomal ends, which serves a 
protective role during cell division. Telomere shortening occurs with each round of cell 
division until a finite number of cycles have been reached before cell senesces and 
undergoes apoptosis.  Telomerase is an enzymatic complex comprising of the TERT 
enzyme, which is responsible for telomere synthesis. In humans, telomerase are inactive in 
mature hepatocytes, whereby liver cells undergo normal replicative senescence and dies 
eventually. In HCC, frequent and a recurrent somatic mutation in the TERT promoter region 
results in reactivation of Telomerase in up to 59% of patients in a HCC cohort [70]. The 
reactivation of telomerase marks the key event during malignant transformation from a  
 
Fig. 1.1 Cirrhosis as a cancer field during malignant tumour 
transformation  
A sequence of genetic events marks the malignant transformation of 
preneoplastic lesions in ultimately leading up to tumour initiation and 
progression. Figure adapted from [66]. In this paradigm, TERT promoter 
mutation is shown to occur early on during the transformation sequence, which 
progressively gives way to several more cancer gene mutations during 
advanced HCC 
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neoplastic lesion into a HCC [70,71]. Furthermore, TERT promoter mutations were 
proposed to be an early recurrent somatic gene mutation as observed by the progressive 
increase in gene mutations from 6% in LGDN to 19% in HGDN and eventually increasing 
to 61% in early HCC [70].    
The WNT/β-catenin pathway plays an indispensible role during embryonic development. 
This oncogenic pathway is frequently activated in HCC via an activating mutation of 
CTNNB1 (encoding for B-catenin) in 11%-37% of HCC patients and inactivating mutation 
of the inhibitory complexes of AXIN or APC [72, 73].  
 
The p53 cell cycle pathway is altered in at least 50% of the HCC patients, with frequent 
inactivating mutations in the TP53 tumour suppressor gene [74]. Further genetic mutations 
in other component of this cell cycle pathway, like CDKN2A, and RB1 were found to be 
inactivated in HCC tumours characteristic of poor prognosis [75]. 
 
Epigenetic alterations allows for reversible modifications on the genomic level without 
changing the DNA sequence. Recent advances in sequencing technologies have made 
possible the identification of a novel class of non-coding RNAs (ncRNAs), the PIWI-
interacting RNA (piRNA) piR-Hep1, which are upregulated in more than 50% of the HCC 
tumours being screened [80]. Inactivating mutations in HCC have also been seen in ARID1, 
ARID2 that are part of chromatin remodeling complexes [77]. Somatic alterations in the 
methylation writer family, mainly in MLL1, 2, 3, and 4 are similarly frequent in HCC. As 
limited work has been performed to explore the epigenetic aspects during HCC 
development, the functional consequences of a deregulation in these epigenetic modifiers in 
HCC awaits to be further explored [76, 77]. 
 
The Oxidative stress pathway is altered by recurrent activation of NRF2 or inactivating 
mutations of KEAP. Activation of NRF2 in tumour cells was shown to confer a protective 
role against chronic oxidative stress and cell death [78]. 
 
PI3K/AKT/mTOR and the RAS/MAPK growth factor receptor-signaling pathway are 
activated in around 5-10% of HCC cells. An activation of the AKT/mTOR pathway was 
shown to occur mainly via amplifications of the CCND1 locus, activating mutations of the 
PI3KCA and inactivating mutations of TSC1 or TSC2 [79].  Altogether, the activation of 
this growth factor signaling pathways in HCC likely accounts for the enhanced cell 
proliferative abilities of these tumour cells [79]. 
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1.4 Metabolic syndrome and HCC burden 
 
1.4.1 Obesity, inflammation and HCC 
 
As previously mentioned, the risk of developing HCC are affected both by genetics 
and environmental factors including history of HBV or HCV infection, alcohol abuses as 
well as a conundrum of metabolic–related disorders like obesity, diabetes, fatty-liver 
diseases etc. In recent years, there has been a surge in the rates of obesity in both developing 
and developed nations, with one quarter of the population in the U.S deemed to be obese 
(BMI > 30 kg/m
2
) [1]. This obesity epidemic has been paralleled by a rise in prevalence of 
the metabolic syndrome, a collective term referring to disorders ranging from obesity to 
hypertension, hyperlipidaemia, insulin resistance to type-2 diabetes (T2D).  
 
1.4.2 A potential link between metabolic syndrome and HCC 
 
Several epidemiological and clinical studies have confirmed the importance of 
obesity as an independent risk factor for HCC [3, 4]. Notably, the risk of cancer-related 
death was significantly associated with obesity for multiple difference types of cancer. In a 
meta-analysis study, the relative risk for HCC-related death was reported to be 4,5 times 
higher in men with a high BMI ≥ 40kg/m2 [2].  
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in 
the absence of alcohol abuse and other known liver disease and occurs commonly as a 
manifestation of obesity-related metabolic syndromes (6). Up to 90% of obese patients and 
70% of T2D patients have been diagnosed with some sort of fatty liver diseases (5).  In the 
absence of proper diet or weight management, 12-40% of the patients with NAFLD 
progresses to non-alcoholic steatohepatitis (NASH) and 15-33% of those with NASH 
develop cirrhosis, which paves the transformation from preneoplastic lesion towards HCC 
development [7, 8, 62] as outline in Fig. 1.2. 
Obesity, as a state associated with chronic low-grade systemic inflammation, has 
been postulated to be a main contributor during this progression from NAFLD – NASH- 
fibrosis- cirrhosis and finally to HCC [9]. In obese individuals, adipocytes undergo 
hypertrophy due to the accumulation of excess lipids. These hypertrophic adipocytes secrete 
free fatty acids (FFA) into the surroundings, which can activate immune cells including liver 
macrophages and kupffer cells. Altogether, these adipocytes and immune cells secrete pro 
inflammatory cytokines like TNF-α, IL-6, IL-1β, IL-8, IL-10, IL-17, IL-18, as well as 
adipokines-like leptin and adiponectin [10,11,12,13,14]. In the presence of excessive 
proinflammatory adipokines and cytokines, kupffer cells and hepatocytes are further 
stimulated to produce more cytokines, resulting in an inflammatory cascade in the liver. 
Several of these cytokine-signalling pathways have been separately demonstrated to be 
pivotal during this state of chronic liver injury, marking the progression from NAFLD to 
NASH, liver cirrhosis and finally towards liver carcinogenesis [15]. Furthermore, obesity- 
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associated inflammation has also been identified to directly contribute to the development of 
metabolic disorders like atherosclerosis and insulin resistances during T2D [16, 17]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4.3 Genetic instability and hepatocyte apoptosis correlate with a risk for HCC  
Independent of all the underlying etiology leading up to chronic liver diseases 
(CLD), liver tissues from CLD patients all displayed varying degrees of chronic hepatocyte 
damage [18]. Mechanistically, it has been reported by the authors in [19] that the removal of 
damaged hepatocytes during the maintenance of liver homeostasis is regulated by factors 
involved in programmed cell death, namely Caspase 8 and receptor interacting kinase 1 
(RIPK1).  More recently in 2017, another group established that the concomitant hepatocyte 
apoptosis and proliferation seen during CLD acts as a decisive determinant of subsequent 
HCC development in mouse and human CLDs [20]. In these hyper-proliferative and hyper-
apoptotic livers from CLD patients and mouse models, the carcinogenic effect from
Fig. 1.2 The pathological progression from benign hepatic steatosis to 
NASH/cirrhosis and eventually to HCC formation 
Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of the 
metabolic syndrome and is characterized by simple steatosis without obvious 
signs of necrosis and inflammatory activities.  The percentages above provide an 
estimate of affected subjects at a current stage, which will progress onto the next 
clinical stage. Non-alcoholic steatohepatitis (NASH) is an aggressive form of 
hepatic steatosis marked by necroinflammatory activities. The sequential 
progression from NASH/cirrhosis to malignant transformation during HCC is 
believed to involve chronic cycles of inflammation-necrosis-regeneration along 
with mutation of tumour related genes. Figure adapted from [62] 
 
 
NAFLD/ 
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replication errors that usually occurs stochastically is drastically increased [20]. The authors 
thereafter postulate that the levels of hepatocyte apoptosis and DNA damage serves as a 
predictive risk factor for subsequent HCC development in CLD patients. This finding further 
highlights and provides a mechanistic link for the correlation between CLD patients to 
develop HCC vs the severity and duration of their liver damage conditions as seen in most 
HCC epidemiological data [21,22,23].  
 
 
2 TRIP13- An overview of key cellular functions   
 
2.1 TRIP13 as a key regulator of chromosomal processes during cell 
division 
 
Cell mitosis and meiosis are key events during development, where a series of tightly 
regulated chromosomal events occur to ensure a faithful transmission of genetic materials. 
AAA
+
-ATPase (ATPase Associated with diverse cellular Activities) are multi-subunit ATP 
hydrolases that mediate a conformational change in its targets, during which changes in the 
complex assembly in turn affect cellular signalling or activities [24]. TRIP13 is a member of 
this ATPase family and has been described to regulate key chromosomal events during cell 
meiosis and mitosis. Different studies have shown TRIP13 to be involved in a myriad of 
processes during G2/prophase of meiosis. These findings include its role as a checkpoint 
activator during synapsis defects and double strand break (DSB), which are intrinsically 
linked to its role in establishing homologous recombination and DSB repair strictly between 
homologous pairs [25, 26, 27].  
 
TRIP13 has been recently described to be a novel mitotic checkpoint regulator 
during the transition from metaphase-to-anaphase and in promoting mitotic progression [28, 
29]. The mitotic checkpoint is a fail-safe mechanism to ensure proper chromosomal 
segregation and genetic transmission to daughter cells during cell division. The spindle 
assembly checkpoint (SAC) is activated whilst its downstream mitotic checkpoint complex 
(MCC) is assembled when a defective kinetochore-microtubule attachment is detected [30]. 
The MCC is composed between BubR1, Bub3 and closed Mad2 (C-Mad2) which directly 
binds to Cdc20 (an APC activator) to inhibit the activity of the anaphase promoting 
complex/cyclosome (APC/C) [30]. The SAC is silenced once all the sister chromatids have 
been properly attached and bi-oriented at the metaphase plate, as shown in Fig. 1.3.  
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2.1.1 TRIP13 and p31comet during mitotic checkpoint silencing 
 
P31
comet
 is a mitotic checkpoint silencing protein that can initiate the disassembly of 
the MCC by directly binding to C-Mad2 and displacing BubR1/Bub3 from this complex [31, 
32]. A picture emerges such that P31
comet
 recruits TRIP13 to the kinetochores during which 
these two factors coordinate the disassembling and silencing of the mitotic checkpoint 
signals [28, 29]. In order for Cdc20 to be released during MCC disassembly, C-Mad2 needs 
to be actively remodelled into the inactive open conformation of O-Mad2. The ATPase 
activity of TRIP13 was found to be essential in driving this ATP-dependent conformational 
transition from C-Mad2 to O-Mad2 [33]. After Cdc20 is released following a disassembly of 
MCC and a halt in the checkpoint signalling, the activated APC/C then drives the transition 
from metaphase to anaphase [28, 29] as seen in Fig. 1.3.  Further highlighting the essential 
role of TRIP13 during checkpoint exit, authors from [34] found that besides the inability to 
inactivate MAD2, TRIP13-depleted cells were similarly unable to activate the SAC. In other 
words, the activation and inactivation of the SAC were both dependent on TRIP13-mediated 
activities [34]. 
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Fig. 1.3    Schematic organization of the human TRIP13 and the proposed 
model for its role in mitotic checkpoint silencing 
(A) TRIP13 contains one AAA
+
-ATPase domain that is located between 171-
323 residues of which is preceded by a non-catalytic NTD. Like many other 
AAA
+
-ATPase proteins, it is suggested that TRIP13 likely assembles itself into 
a homo-hexameric oligomer. (B) Spindle assembly checkpoint (SAC) and 
MCC are activated by the presence of unattached kinetochores. The MCC is 
composed of BubR1 (purple), Bub3 (not shown), CDC20 and closed Mad-2 (C-
Mad2) which directly binds and inhibits the anaphase promoting 
complex/cyclosome (APC/C), inhibiting anaphase onset. (C) Model depicts the 
role of TRIP13 in disassembling the MCC and promoting mitotic progression. 
When kinetochores are properly attached, the silencing of the SAC is initiated. 
p31Comet binds to the existing MCC and displaces BubR1, whilst delivering 
CDC20:C-Mad2 to TRIP13 for further conformational conversion (to O-Mad2) 
and disassembly. The release of CDC20 activates the APC/C, which then 
drives the onset of anaphase. (Figures adapted from [63, 81]) 
 
 2   INTRODUCTION 
    9 
 
 
2.2 Upregulated expression of TRIP13 in several human cancers 
 
2.2.1 Genomic instability and aneuploidy in cancer 
Chromosomal instability (CIN) and aneuploidy are persistent hallmarks of human 
solid tumours [38]. Given the essential roles of TRIP13 in regulating chromosomal events 
during meiosis and mitosis, one of the predicted functions of TRIP13 was to prevent genome 
instability. This was reflected by many studies that have shown either an amplification of the 
TRIP13 gene or an overexpression of TRIP13 in several cancers [35, 36, 37, 43, 44]. The 
CIN signature identifies a set of top-ranked genes that are common upregulated in tumour 
cells displaying functional aneuploidy. Most of the genes identified to be associated with 
CIN, for instances TPX2, PRC1, FOXM1 and TRIP13 are critical regulators during DNA 
replication, SAC signalling, chromosomal segregation and cytokinesis [37]. Net 
overexpression of this CIN signature was a predictor for poor clinical outcome in 6 different 
cancer types, namely breast cancer, lung cancer, medulloblastoma, glioma, mesotheliomia 
and lymphoma. Strikingly, the authors also reported the ability to stratify tumour grades 
from multiple tumour types using the CIN signature, with more aggressive cancer 
phenotypes typically displaying higher CIN signature expression [37]. 
 
Reflecting the findings that a loss of genome stability is an essential step during 
malignant transformation, TRIP13 was listed amongst multiple breast cancer signatures due 
to its overexpression in transcriptome profiling across tumour samples from patients 
associated with poor clinical outcomes [35, 36]. Furthermore, knocking down of TRIP13 
inhibited cell proliferation in breast cancer cell lines, highlighting roles of TRIP13 during 
mitotic progression and cell growth [28]. 
 
2.2.2 Chromosomal instability (CIN) in liver cancer 
 
The relevance of CIN and the importance of functional aneuploidy in HCC was left 
unknown as this cancer type was not included as part of the previous study in defining the 
CIN signature of cancer patients [37]. Evidence suggesting that CIN similarly plays a role in 
liver cancer was derived from these early observations. Firstly, the presence of CIN and 
aneuploidy were correlated with the progression of HCC. Secondly, induction of aneuploidy 
in HCC cells were associated with elevated levels of telomere shortenings and centromere 
abnormalities, all of which were indicative of CIN phenotypes [40,41].  
 
Hippo/Yap signalling pathway in inducing CIN in liver cancer 
-Function implications of TRIP13 as part of the CIN signature?  
Recently in 2017, the authors [39] demonstrated that the CIN signatures as identified 
previously [37] are similarly detectable in HCC tumour tissues and stratifies a subgroup of 
HCC patients with poor clinical outcome. The Hippo pathway and its downstream effector  
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yes-associated protein (YAP) are key regulators of tissue and organ size homeostasis where 
its deregulation was implicated in hepatocarcinogenesis [42]. Overexpression of YAP was 
sufficient to induce an upregulation of CIN signature genes along with chromosomal 
aberrations in hepatocytes of transgenic mice (YAP
S127A
) that were expressing a 
constitutively active form of YAP [39].  In human HCC tissues, high nuclear expression of 
YAP correlated with CIN signature expression and aneuploidy. It was then reported that 
YAP cooperates with FOXM1 in contributing to the expression of CIN gene signatures and 
chromosomal aberrations during hepatocarcinogenesis [39].  Interestingly, TRIP13 was 
identified as one of the top 25 ranked CIN signature genes (CIN25) along with FOXM1 and 
MAD2L1, which were induced by an overexpression of YAP in liver tumour cells from this 
study. Patients displaying a high CIN25 gene expression were correlated with poor survival 
and early cancer recurrence. Given the role of YAP in regulating CIN gene expression in 
HCC, it is plausible that TRIP13 along with several downstream target genes from 
YAP/FOXM1 contributes towards chromosomal instability in HCC patients displaying 
CIN25 signatures [39].   
 
2.2.3 Role of TRIP13 in promoting DNA repair and chemoresistance 
 
Squamous cell carcinoma of the head and neck (SCCHN) is an aggressive cancer 
with high mortality and recurrence rate due to rapid acquiring of treatment resistance by 
these carcinoma cells [45]. An oncogenic role of TRIP13 was first reported in SCCHN. The 
upregulated expression of TRIP13 was shown to promote aggressive tumour growth and 
treatment resistance, supposedly mediated via the roles of TRIP13 in DNA damage repair 
[45]. TRIP13 copy number and gene expression was found to be upregulated in SCCHN 
patients when compared against non-tumourous mucuosa tissues. The oncogenicity of 
TRIP13 was established via these key findings: Firstly, overexpressing TRIP13 transformed 
non-malignant fibroblast cells during a clonogenic assay. Secondly, overexpressing TRIP13 
in a SCC cell line expressing low endogenous levels of TRIP13 triggered an increase in cell 
proliferation, migration and invasiveness as compared to control cells. This was further 
validated in vivo where these TRIP13-overexpressing tumours grew much quicker than 
control tumours after being implanted into mice. Mice with TRIP13 overexpressing tumours 
had poorer survival rates than mice with control tumours presumably due to the larger 
tumour burden in these animals. This tumourigenic effect was reversed when TRIP13 was 
depleted, as it was demonstrated by doxycycline-induced shTRIP13 KD that significantly 
arrested tumour growth as compared to doxycycline treated control groups in xenograft 
models [45].  
Adding on to the oncogenic role of TRIP13 in SCCHN, the authors further reported a 
mechanistic involvement of TRIP13 in promoting treatment resistance via enhanced repair 
of DNA damage. Using a mass spectrometry screening to identify TRIP13-interacting 
partners, several non-homologous end joining (NHEJ)/ DNA repair group proteins like 
KU70, KU80 and DNA PKcs were identified, suggesting a role of TRIP13 in NHEJ. In 
SCCHN, efficient repair of radiation and chemotherapy-induced double strand breaks ( 
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DSBs) was identified as one of the leading causes of chemoresistance and early tumour 
recurrence. This study provided an important finding that the upregulated expression of 
TRIP13 confers treatment resistance in SCCHN, emphasizing the importance of targeting 
NHEJ to overcome treatment failure [45]. 
 
2.3 A novel role of TRIP13 in liver regeneration and HCC 
tumourigenesis 
 
 
2.3.1 TRIP13 is upregulated in liver cancer 
 
The mortality rates from liver cancer is the second highest worldwide, presumably 
due to the lack of early presenting signs and symptoms. Patients often present with advanced 
stage of HCC when first being diagnosed, which further limits their treatment options. 
Depending on the stage of liver cancer, some common treatment options include surgical 
resection of the tumour (partial hepatectomy), liver transplantation, radiotherapy, 
conventional chemotherapy, and more recent targeted and immunotherapy [66]. Vascular 
endothelial growth factor (VEGF), platelet derived growth factor (PDGF) and fibroblast 
growth factor (FGF-2) are established proangiogenic factors that play key roles during HCC 
development. Sorafenib was the first multi kinase inhibitor drug targeting the 
VEGF/VEGFR to be approved that has demonstrated survival benefits in advanced HCC 
patients [82, 83]. Despite numerous targeted therapies that made it through to clinical trials, 
few have been demonstrated to be effective in advanced-stage HCC [66]. Due to the unmet 
medical needs, novel pathways and cellular mechanisms during hepatocarcinogenesis need 
to be further explored in order to identify new therapeutic targets or prognostic biomarkers.   
In an effort to identify novel regulators in HCC, a former colleague in the lab, Dr. 
Bettina Meissburger, reviewed publicly available expression data of genes deregulated in 
HCC (E-GEOD-25097). From these expression data, TRIP13 was found to be strongly 
upregulated in tumour tissues compared to non-tumour tissues (Fig. 1.4A) in the liver.  
A HCC mouse model was set up by injecting Diethylnitrosamine (DEN) to young 
mice (2 weeks) and to observe for HCC formation at later age of 30 weeks. Trip13 
expression was found to be significantly upregulated in liver tumours of DEN-injected mice 
compared to healthy livers from the control group (Fig. 1.4B). Tissue micro array (TMA) 
from a cohort of HCC patients revealed similarly an increase in TRIP13 staining exclusively 
in the hepatocytes (data not shown).  
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2.3.2 TRIP13 is induced in partial hepatectomy and fatty liver diseases 
 
The novel role of TRIP13 in hepatocyte regeneration and tumourigenesis was 
unveiled through various complementary in vivo approaches. Interestingly, the expression of 
TRIP13 was similarly upregulated in various mouse models of fatty liver and steatohepatitis, 
from ob/ob, db/db mice to high fat diet and methionine-choline deficient diet-induced 
obesity in animals (Fig. 1.5A). Reflecting the role of TRIP13 during mitotic progression, an 
induction of TRIP13 was noted at 48 hrs post operation after performing partial hepatectomy 
(PHX), when cell proliferation was at its peak during liver regeneration (Fig. 1.5B). 
Subsequently, this PHX procedure was performed again to investigate the regenerative 
ability of hepatocytes when depleted of Trip13. To knockdown Trip13 specifically in the 
liver, mice were injected with Adeno-associated virus (AAV) containing miRNA against a 
non-targeted control (NTC) sequence or Trip13, one-week prior to PHX (Fig. 1.6).  
Fig. 1.4 Expression of Trip13 in human HCC and mouse model of 
DEN-induced HCC    
(A) TRIP13 expression in a HCC gene expression profile (accession number: 
E-GEOD-25097) where TRIP13 is significantly upregulated in tumour tissues 
compared to non-tumour tissues and healthy liver tissues.                                 
(B) Diethlynitrosamine (DEN)- induced HCC mouse model was established by 
injecting DEN to young mice at 2 weeks of age and observing for tumour 
formation by 30 weeks of age. Trip13 expression was significantly upregulated 
in liver tumours from DEN-injected mice vs healthy liver from control-injected 
mice.  
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Expectedly, the number of proliferating cells in the control liver was strongly 
induced during liver regeneration after the operation. Mice depleted of Trip13 specifically in 
the liver showed hepatocytes with a decreased ability to regenerate, as seen by a decrease in 
the expression of a mitotic cell marker, proliferating cell nuclear antigen (PCNA), in liver 
sections (Fig. 1.6).  
 
 
 
 
 
 
 
 
 
Fig. 1.5    Trip13 is upregulated in mouse models of fatty liver diseases and 
during liver regeneration 
(A) Trip13 expression is upregulated in murine genetic models of insulin 
resistance as well as diet-induced fatty liver diseases. (B) Partial hepatectomy 
(PHX) was performed in the liver of mice and liver tissues were harvested 
24hrs and 48hrs post PHX. Gene expression of Trip13 was shown to be induced 
48 hours post PHX on both mRNA and protein levels. 
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Fig. 1.6 Trip13 is essential during hepatocyte regeneration after partial 
hepatectomy (PHX) operation in mice 
1 week prior to the PHX procedure, mice were injected with Adeno-associated 
virus (AAV) containing miRNA targeting either a control or a Trip13 sequence. 
Sham operated mice served as a negative control for the procedure itself. (A) 48hrs 
after the PHX procedure, liver tissues were harvested and processed for histology 
and microtome sectioning. Liver sections were immunostained with PCNA 
(proliferating cell nuclear antigen) to detect for cell proliferation. PCNA staining 
was much weaker in Trip13-depleted liver sections as compared to liver section 
from control AAV injected mice after PHX. (B) The number of proliferating cells 
(PCNA positive nuclear) was manually counted in each field of view (FOV) and 
the average from 5 FOV is shown.   
 
A
B Sham-control 
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To examine the oncogenic potential of TRIP13 during tumourigenesis, HCC cells 
were infected with lentiviral particles harbouring either the shRNA control or the shRNA 
TRIP13 construct. These HCC cells were then implanted subcutaneously into mice and 
monitored for tumour growth in vivo. In line with the growth-promoting effects of TRIP13 
as seen above in Fig. 1.6, tumours developed from TRIP13-depleted HCC cells were much 
smaller as compared to the control tumours in Fig. 1.7. Furthermore, knockdown of TRIP13 
significantly impaired in vitro cell growth across all HCC cell lines being investigated        
as shown in the later results section (Fig. 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B
Fig. 1.7 Trip13 depletion inhibits tumour growth in a tumour 
xenograft model 
HLF and Hepa1-6 cells were infected with lentiviruses containing either control 
shRNA or Trip13-targeting shRNAs. These HCC cells were implanted into the 
left flank of mice to monitor tumour growth in vivo. The experiments were 
terminated and tumours were harvested when palpable tumour reaches more than 
a size of 15 mm in any dimensions. (A) Picture shows tumours being harvested 
from BalbC mice implanted with Hepa1-6 cells from one representative 
xenograft. Trip13-depleted Hepa1-6 cells resulted in much smaller tumours 
compared to control Hepa1-6 cells. (B) Weight of tumours derived from animals 
being injected with Trip13-depleted Hepa1-6 cells were significantly lower 
compared to control Hepa1-6 cells.  
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Cell invasiveness of HCC cells through transwell chambers were severely impeded 
post TRIP13 depletion, with HLF cells showing the most dynamic response in this assay 
(Fig. 1.8B), suggesting an additional role of TRIP13 during HCC cell motility. Cell cycle 
analysis subsequently revealed that depleting TRIP13 resulted in more cells in the G1 phase 
for Hepa1-6 and Huh7 whilst more cells accumulated in G2 phase for HLF cells as compared 
against control cells (Fig. 1.8A) Altogether, the findings above strongly supported a growth 
regulatory role of TRIP13, both during hepatocyte regeneration and tumourigenesis, where 
the function of this frequently overexpressed protein has yet to be characterized in liver 
cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
B
Fig. 1.8 Trip13 depletion in HCC cells affects cell cycle and cell 
invasiveness through transwell assays 
Cell cycle analysis using propidium iodide (PI) staining was performed to compare 
between control and Trip13 depleted HCC cells. (A) Hepa1-6 and Huh7 cells were 
harvested and fixed in ethanol before being further processed for cell cycle 
analysis using FACscanto. A shift in cell cycle phases is detected in Trip13-
depleted cells, with more cells being accumulated in the G1 phase vs the control 
cells. (B) Cell migration of HCC cells post Trip13 depletion was examined using 
transwell inserts with 8 μm pore size. Cells were seeded into transwells containing 
serum-free media, whilst the lower chambers were filled with media+10% serum. 
16 hours post incubation; cells that migrated through the transwell membrane were 
fixed, stained with 0.1% crystal violet and then imaged. The area of stained cells 
was analysed with image J.  
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2.3.3 Involvement of TRIP13 in the mTOR-signalling axis? 
 
Preliminary unpublished data from the lab suggested an oncogenic role of TRIP13 in 
the mTOR-signalling axis. A decrease in phosphorylation and activation of key mTOR 
downstream regulators like p-S6K, p-eIF4B and p-4E-BP1 were seen in TRIP13-depleted 
HCC cells in Fig. 1.9. The EGF signalling axis which acts upstream of the mTOR pathway 
was similarly impaired, a decrease in receptor activation of EGF along with a decrease in 
expression levels of this receptor is detected in TRIP13-depleted HCC cells (data not 
shown). The initial hypothesis is such that TRIP13 could be involved in an oncogenic EGF-
mTOR signalling axis during HCC development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.4 Identifying novel interaction partners of TRIP13 in HCC 
 
Given the roles of TRIP13 in oncogenic signalling pathways, a mass spectrometry 
(MS) was performed with aims of identifying TRIP13-interacting partners, which might 
account for these TRIP13-mediated effects. To this end, endogenous TRIP13 was pulled 
down from HLF and Huh7 cells and interaction partners were analysed by MS. Out of the 
proteins that were enriched to be interacting with TRIP13, 39 proteins were identified to be 
common interacting partners of TRIP13 from both cell lines (Fig. 1.10). Based on KEGG 
analysis, some of the main pathways identified were involved either in cell cycle regulation, 
transcriptional co-regulation and DNA damage repair (data not shown). Out of this pool of 
enriched targets from the MS analysis, candidates with a putative role as transcriptional  
Fig. 1.9    TRIP13 depletion downregulates 
key regulators in the mTOR-signalling axis 
Regulators of the mTOR-signalling pathway 
were immunoblotted in TRIP13-depleted HCC 
cells. HLF cells depleted of TRIP13 showed 
decreased activation/phosphorylation of key 
factors in the mTOR pathway like S6K, eIF4B, 
4E-BP1 and Cyclin D1. β-actin was used as a 
loading control in this immunoblot. 
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regulators/co-regulators were picked for further analysis. 2 of this selected targets, SIN3A 
and SAP130 have been described to form part of the histone deacetylase (HDAC) complex 
during transcriptional repression [48, 50]. Efforts aimed at characterizing the interactions 
between TRIP13 and its interaction partners along with the functional relevance of this 
interaction during tumourigenesis forms the bulk of the work in this thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Huh7 HLF 
Criteria: > 70% spectrum enrichment in 
TRIP13 sample versus GFP 
  
133 136 
39 
Fig. 1.10 Mass spectrometry-based identification of TRIP13 
interaction partners 
(A) Representative Western blot of TRIP13-IP in Huh7 and HLF cells. Cells 
were harvested from a 15 cm dish and cell lysates were subjected to a typical 
agarose beads protocol for protein pull down. Precleared cell lysates were 
incubated with equal amounts of either a control GFP antibody or TRIP13 
antibody on a rotating wheel at 4°C overnight. Endogenous TRIP13 proteins 
eluted from the pulldown were verified via western blotting. For analysis of 
interaction partners by mass spectrometry, eluates were run on a gradient gel, 
Coomassie stained and submitted for protein analysis. (B) Venn diagram of 
proteins identified by mass spectrometry. 39 proteins were identified that 
interacts with TRIP13 in both HLF and Huh7 HCC cell lines.    
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2.4 SIN3A— role as a transcriptional regulator in the context of cancer? 
 
2.4.1 Structure and function of SIN3A 
Sin3 (SWI-independent-3) family was first identified in a genetic screen to study 
mating-type switching in yeast cells [47]. This protein family is highly conserved from 
human to yeast, with its roles described as both an enhancer and repressor of gene 
expression [46]. In mammals, the Sin3 family consist of two isoform members, Sin3A and 
Sin3B that have both overlapping and distinct functions [48]. Sin3 proteins have 4 paired 
amphipathic α helices (PAH) that share structural similarities to the helix-loop-helix 
dimerization domains of the Myc family of transcription factors. The other two conserved 
domains include the histone interacting domain (HID) and the highly conserved region 
(HCR) in the c-terminal [48, 49] as illustrated in Fig. 1.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.11   Schematic representation of structural domains in Sin3 protein  
Sin3 contains 6 highly conserved domains including 4 PAH domains, along 
with one HID and one HCR domain at the C-terminal. Cellular functions of 
Sin3 as both a positive and negative regulator of gene expression is shown 
above. The Sin3/HDAC complex is a class one HDAC-containing complex 
consisting of several chromatin-associated factors as shown above in green.  
The PAH2 domain interacts with a subset of transcription factors containing a 
conserved sequence called the Sin-interacting domain (SID). In a targeted 
therapy against Triple-negative breast cancer (TNBC) discussed in section 
2.4.3, SID decoys were used to block the interaction between PAH2 domain 
of Sin3A and its interaction partners. Figure adapted from [49].     
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Sin3 has been described as a master transcriptional regulator due to its ability to act 
as a molecular scaffold to recruit several chromatin-associated factors like HDAC1/2, 
RBBP4/7, SDS3, SAP30/130/180, RBP1 to form what is known as the Sin3/HDAC 
complex. This complex transcriptionally regulates several genes and diverse cellular 
functions due to an ability to bind to target promoters with or without target specific 
transcription factors [48, 50].  
The Sin3/HDAC complex is commonly referred to as the “co-repressor complex” 
due the recruitment of HDAC activities being linked to promoter hypoacetylation and gene 
repression [48, 51]. Recent evidence points to a versatile role of Sin3 in both gene activation 
and repression. This is best illustrated in the regulation of the pluripotency factor, Nanog, in 
embryonic stem cells (ESC). The recruitment of Sin3/HDAC by Sox-2 activates the 
expression of Nanog in proliferating ESC whilst p53-mediated recruitment of the same 
complex silences Nanog during differentiation  [51, 52]. The mechanism of gene activation 
mediated by Sin3 is not well characterized and this dual mode of gene regulation seems 
dependent on both the cellular and molecular conditions and upon interactions with different 
chromatin-associated regulators [48, 51].  
 
2.4.2 SIN3A as a tumour suppressor in cancer 
  
SIN3A was identified as one of the interaction partners for TRIP13 during our MS 
screening using whole cell lysates from HCC cells (Fig. 1.10). Given that SIN3A acts as a 
master regulator of several essential genes in critical cellular functions, it is hardly surprising 
that aberrant gene regulations mediated by this protein complex could have far-reaching 
consequences during cellular malignancies [49, 54]. Recruitment of Sin3A/3B by the Mad-
Max heterodimer was shown to be essential in antagonizing transcriptional activations 
driven by the proto-oncogene Myc during cell proliferation and transformation [53-55].  
Other than Mad-Max dependent negative regulation of c-Myc, Sin3/HDAC complex was 
shown recently to direct antagonize c-Myc activity via deacetylation and destabilization of 
the Myc protein [54].  A tumour suppressor role of Sin3A was demonstrated using the 
Drosophila (multiple endocrine neoplasia type 2) MEN2 model [56]. The drosophila 
homologue of human Sin3A, dsin3, was identified to be an important regulator of EMT, 
where the RNAi-mediated depletion of dsin3 led to strong enhancement of cell migration 
and mesenchyme phenotypes [56]. 
 
2.4.3 SIN3A as a tumour oncogene in promoting tumourigenesis in Triple negative 
Breast cancer (TNBC) 
 
Triple negative breast cancer (TNBC) is an aggressive and poorly differentiated 
subtype of breast cancer that is diagnosed one out of five breast cancer patients. Currently, 
no forms of hormonal/targeted therapies are available due to the absence of the estrogen 
(ER), progesterone (PR) and EGFR receptors in TBNC tumours [57, 58]. 
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SIN3A was demonstrated to mediate oncogenic functions in TNBC via protein-
interactions between the PAH domain of SIN3A and specific interaction partners [59]. The 
PAH2 domain of SIN3A is well characterized and is known to interact specifically with a 
subset of transcription factors that contain a conserved sequence called the SIN3-interaction 
domain (SID), see Fig. 1.11. In an attempt to understand the consequences of targeting the 
PAH2 domain of SIN3A in TNBC, the authors from this study [61] expressed a SID decoy 
to specifically disrupt PAH2 domains of SIN3A from binding to SID-containing partners. 
The SID decoy led to epigenetic reprogramming and re-expression of TNBC-associated 
silenced genes of ER and retinoic acid receptor along with the downregulation of markers 
for cancer stem cells and epithelial-mesenchymal transition (EMT) [59-61]. The re-
expression of these hormone receptors made this previously “undruggable” cancer subtype 
“druggable” again with hormone-targeted therapies [61]. This study highlighted the 
discovery of an interaction between SIN3A and a SID-containing adaptor protein, PF1, [59] 
as essential in the oncogenic maintenance of EMT and CSC phenotype in TNBC. 
The decrease in CSC functions of TNBC by SID treatment reflects previous reports 
of the positive role of Sin3A in promoting pluripotency in proliferating ESC [52]. This 
finding stands in contrast with the tumour repressor role of Sin3A/HDAC complexes as a c-
Myc-antagonist. At this point, the conflicting roles of SIN3A as either a tumour suppressor 
or an oncogene remains controversial. The dual mode of transcriptional regulation mediated 
by SIN3A is likely to be context dependent and subjected to the dynamics of its spatial-
temporal associations with different factors, as reflected by numerous examples discussed 
above [49-51]. 
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Aims of the study 
  
In lieu of the unmet medical needs for improving targeted-therapies and diagnostic 
biomarkers in liver cancer, it was of paramount interest in characterizing novel targets and 
mechanisms involved that were important during hepatocarcinogenesis.  
Previous unpublished work from the lab has shown an oncogenic role of TRIP13 in human 
and mouse HCC through various experimental mice models of HCC and expression data sets 
from HCC patients.  
 
The aim of the present study was to further characterize the mechanisms through which 
TRIP13 exerts its oncogenic effects during liver cancer growth. We hypothesized that 
TRIP13 could be regulating or be part of a central regulator pathway that determines cellular 
outcomes in terms of cell survival, growth or death.  
 
To do so, we adopted various complementary in vitro approaches to examine for the 
oncogenic functions of TRIP13 in several HCC cell lines including HLF, Huh7, HepG2 and 
Hepa1-6. Cell viability, proliferation and apoptosis upon siRNA-mediated KD of TRIP13 
were determined in here. Additionally, we aim to examine the expression levels of key 
oncogenic signalling factors to identify upstream and downstream pathways through which 
TRIP13 is involved in. The oncogenic relevance between TRIP13 and its interaction partner 
of SIN3A, which was identified from a mass-spectrometry analysis, were characterized. In 
order to determine whether this interaction was functionally relevant for cell growth, we 
examined for effects on HCC cell lines upon either single siRNA KD of TRIP13, SIN3A or 
both. Using lentiviral-mediated shRNA KD of SIN3A, we plan to establish a stable HLF cell 
line (shTRIP13+shSIN3A) for use in subcutaneous tumour implantation studies in order to 
accurately recapitulate this relationship in vivo.  
 
From all the findings above, we aim to dissect the mechanistic framework and provide 
functional annotations on the oncogenic roles of TRIP13 during hepatocarcinogenesis. This 
would serve as an interesting basis for developing novel biomarkers during diagnosis or  
targeted-therapies against HCC.   
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3 Results 
 
3.1 TRIP13 regulates cell growth and proliferation in HCC cells  
We have seen a regulation of TRIP13 during hepatocytes regeneration as well as its central 
role during HCC in human and mice (Fig.1.5 to Fig.1.8). Given these striking in vivo data, we 
were intrigued to further investigate the importance of TRIP13 as an oncogenic factor in 
HCC cells. 
To this end, we first performed siRNA transfections using human HCC cell lines of HLF, 
Huh7 and HepG2 as well as mouse cell line of Hepa1-6. These cell lines were transfected 
either with a non-targeting control (siNTC) or a TRIP13- (human or mouse) specific siRNA 
(Fig. 3.1) to study cell proliferation (Fig. 3.2). Quantitative analysis of mRNA and protein 
levels 3 days post transfection showed that a knockdown of more than 75% of endogenous 
TRIP13 was achieved in all cell lines being utilized (Fig. 3.1).  
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As shown previously in vivo, a depletion of TRIP13 strongly reduced tumour growth in the 
xenograft models. Similarly in here, the knockdown of TRIP13 resulted in a significant arrest 
in cell growth 48hrs post transfection. The severities of siTRIP13-induced proliferation arrest 
in these various cell lines are listed in the order from HLF, Huh7, and HepG2 to Hepa1-6, 
with HLF cells being the most severely impaired (Fig. 3.2A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 Validation of siRNA-mediated knockdown in human and 
mouse HCC cell lines  
The different cell lines were seeded in 12-well plates and siRNA transfections 
were performed the following day in accordance to protocols in section 4. 
Samples were harvested for RNA extraction and protein lysis at 72hrs post 
transfection. (A) mRNA expression levels of TRIP13 are relative to TBP and 
values shown are normalised against the siNTC group. (B) Western blot of 
TRIP13 from HLF and Huh7 cells transfected with siNTC or siTRIP13 siRNAs. 
VCP: Valosin containing protein (loading control).  Data are plotted as mean ± 
SEM. **** p< 0,0001; ***p<0,0002; * p<0,05; vs siNTC determined by two-
tailed welch’s t-test 
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As an alternative readout to assess cell proliferation, we have also utilised the BrdU 
incorporation kit, which determines BrdU incorporation into DNA as a measure for cell 
proliferation (Fig. 3.2B). Cell proliferations were similarly decreased across all HCC cell 
lines examined. Our in vitro data therefore strongly demonstrates that TRIP13 indeed plays a 
central role during cell proliferation.   
Fig.  3.2 TRIP13 regulates cell proliferation in various HCC cells  
24hrs post siRNA transfection, cells are trypsinzed and reseeded into 96-well 
plates with at least 3 repeats per siRNA conditions. (A) Growth rate of cells in 
96-well plates D1 to D4 post transfection were measured by using CCK8 (cell 
counting kit 8). Absorbance at 450nm directly correlates to the number of viable 
cells in the well. (B) Cell proliferation was measured at D3 post transfection 
using a BrdU incorporation kit following protocols in section 1.  Absorbance at 
540nm correlates directly with actively proliferating cells. Values are shown 
normalized to that of the siNTC conditions    
Data are plotted as mean ± SEM. (A) **** p≤ 0,0001; **p≤ 0,01; vs siNTC 
determined by 2-way Anova. (B) * p≤ 0,05 ; ***p≤ 0,001 vs siNTC determined 
by two-tailed welch’s t-test versus siNTC 
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3.2 TRIP13 as a regulator of EGFR  
 
 
3.2.1 EGFR expression is dependent on cellular levels of TRIP13  
Based on our in vivo and in vitro data that supported a pro-tumourigenic role of TRIP13 in 
HCC development, we aimed to further identify and characterize the mechanistic 
involvement of TRIP13 in this context. From TRIP13 depleted HCC cells, we observed a 
decreased expression of EGFR, phosphorylation of key factors in the mTOR signalling 
pathway like E2F, IF4, along with downstream targets like cyclin D (Fig. 1.9).  
Indeed, the EGFR signalling system has been implicated as a key player in the reparative and 
regenerative response of the liver, ranging from early inflammation and hepatocyte 
proliferation to fibrogenesis and neoplastic transformation [115]. EGFR expression and gene 
copy number has been found to be hugely upregulated in more than 50% of the HCC patients 
and tumour samples [116]. This has been accompanied alongside by an elevated expression 
of the EGFR ligands.  
We first hypothesize that the EGFR/mTOR signalling pathway could be involved in here, in 
which a reduced signalling through this pathway could mediate the marked decrease in 
proliferation in TRIP13-depleted HCC cells. In order to investigate this mechanistic link, we 
first determined mRNA and protein expression of EGFR upon TRIP13 knockdown in 
multiple HCC cells (Fig. 3.3). We observed a significant decrease in both mRNA (Fig. 3.4A) 
and protein expression of EGFR (Fig. 3.3) across all HCC cell lines investigated (only data 
from HLF and Huh7 cells are shown in here).   
 
 
 
 
Fig. 3.3 TRIP13 regulates EGFR protein expression in HCC cells  
72hrs post siRNA transfection, cell lysates were harvested for western blot. 
Three repeats per siRNA conditions per cell line were immuno-stained for 
TRIP13, EGFR and VCP (loading control) as shown. 
EGFR 
VCP 
Trip13 
          siNTC      siTRIP13    siNTC     siTRIP13 
             HLF                        Huh7 
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We wanted to address whether manipulating the cellular levels of TRIP13 could affect the 
mRNA expression of EGFR in either ways. To do so, we examined cells that were either 
depleted (siTRIP13) or overexpressing TRIP13 (p-TRIP OE). 
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Fig. 3.4 Cellular levels of TRIP13 affect EGFR mRNA and promoter 
activity in HCC cells  
TRIP13 levels were manipulated by either siRNA knockdown or overexpressed 
via a plasmid vector expressing the full-length sequence of TRIP13 (A) 72 hrs 
post transfection, cells were harvested for RNA extraction and subsequent 
qPCR analysis for TRIP13 and EGFR expression levels. Values are normalized 
against TBP and relative to that of either siNTC or the p-CDNA3.1 (empty 
vector) group. (B) An EGFR-promoter reporter construct (p-EGFR-HRP) has 
been co-transfected along with different siRNA or plasmids in here. The cell 
culture media was collected over D3 and D4 post transfection and the EGFR 
promoter reporter activity was measured with a Dual luciferase reporter assay. 
Relative luminescence values (RLU) correlates directly to the EGFR promoter 
activities. The values shown are relative to that of the control groups of either 
siNTC or p-CDNA3.1 (not displayed in this graph).  Data are plotted as 
mean  ±  SEM. **** p≤  0,0001; **p≤  0,01; vs siNTC determined by 2-way 
Anova. NS indicates non significant differences  
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True indeed, EGFR mRNA expression was down regulated in TRIP13 KD cells and 
upregulated in HCC cells overexpressing the full-length human TRIP13 protein    (Fig. 3.4A). 
To further investigate whether TRIP13 transcriptionally regulates EGFR via its promoter 
activity, we co transfected HCC cells with a human EGFR promoter reporter construct (p-
EGFR-HRP) along with either siTRIP13 or p-TRIP13 OE  (Fig. 3.4B). Similar to changes in 
EGFR levels upon TRIP13 KD or OE, a decrease in EGFR promoter activities were observed 
for TRIP13 KD cells whilst an increase in promoter levels was seen for TRIP13 OE cells. In 
conclusion, our data suggests that EGFR could be transcriptionally regulated by TRIP13.  
 
3.2.2 The EGF pathway does not significantly contributes to TRIP13-dependent cell 
proliferation 
In order to test our initial hypothesis that EGF signalling acts as a downstream mediator in 
conveying TRIP13-dependent effects on cell proliferation, we performed a loss of function 
analysis on cell growth upon EGFR knockdown. In both HLF and Huh7 cells, a successful 
knockdown of EGFR could be seen both on the mRNA and protein levels (Fig. 3.5A, B). The 
knockdown of EGFR resulted only in a minor growth defect in both cell lines (Fig. 3.5C). 
This was particularly so in HLF cells where proliferation impairment became apparent only 
at D4 post knockdown (Fig. 3.5C) as compared to an arrested cell proliferation already at D2 
post TRIP13 knockdown (Fig. 3.2A). Due to the minor effects on growth as seen during 
EGFR knockdown, the initial hypothesis that EGF signalling plays a central role in mediating 
a TRIP13-dependent effect on cell growth could not be confirmed.  
Along the same direction in refuting our initial hypothesis, a microarray analysis from a HCC 
patient cohort in Heidelberg showed that EGFR expression was relatively higher in the non-
tumour samples vs the tumour samples (Fig. 3.6A). In line with our findings thus far, TRIP13 
expression was shown to be significantly upregulated in the tumour samples vs the non-
tumour samples. A spearman correlation analysis was performed between the expression 
levels of TRIP13 and EGFR (Fig. 3.6B). A negative correlation coefficient value of r= -0,272 
was derived from this analysis.  
 
In light of the above findings, we came to the conclusion that the EGF signalling pathway 
does not play a central role in mediating the TRIP13-dependent oncogenic effects as seen 
during proliferation of HCC cells.    
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Fig. 3.5  EGFR knockdown only has a minor effect on cell proliferation in 
HCC cells  
Expression levels of EGFR and TRIP13 D3 post transfection in HLF and Huh7 
cells. Cell growth was assessed between D1 to D3 post siRNA transfection.(A) 
mRNA levels of EGFR and TRIP13 are normalized against TBP and shown as 
relative to the siNTC group.  (B) Blotting for EGFR and TRIP13 with VCP as a 
loading control. (C) Growth rate of cells D1 to D4 post transfection were 
measured by using CCK8 (cell counting kit 8). Absorbance at 450nm directly 
correlates to the number of viable cells in the well Data are plotted as mean ± 
SEM. (A) **** p≤  0,0001; **p≤  0,01; vs siNTC determined by two-tailed 
welch’s t-test. (C) * p≤  0,05 ; vs siNTC determined by 2-way Anova. NS 
indicates no significant differences 
  
B 
 3  RESULTS 
 30 
  
Fig. 3.6  TRIP13 and EGFR expression are not positively correlated 
in HCC cancer 
(A) TRIP13 and EGFR microarray expression data in a HCC patient cohort 
dataset from Heidelberg (In collaboration with Stephanie Roesler from 
Heidelberg). TRIP13 and EGFR expression from tumour samples (N=247) vs 
non-tumour samples (N=239) are compared here. (B) A Spearman correlation 
analysis was performed between expression levels of TRIP13 and EGFR. The 
spearman correlation coefficient R is as stated.  Data are plotted as mean ± 
SEM. (A) **** p≤ 0,0001 vs Non tumour group, unpaired t-test. 
A 
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3.3 Investigating the mechanistic role of TRIP13 in its tumour promoting 
functions 
3.3.1 Identification of TRIP13-interaction partners that could define involved 
regulatory complexes  
In order to decipher the mechanistic framework through which TRIP13 exerts its oncogenic 
function in HCC, a Mass spectrometry-based screening to identify TRIP13 interaction 
partners was performed. As outlined in Fig. 1.10, an immunoprecipitation (IP) approach was 
performed to pull down endogenous TRIP13 protein from both HLF and Huh7 cells. 
Amongst the co-precipitated proteins that were identified from the MS analysis, 39 proteins 
were found to be identical between both cell lines. Intriguingly, amongst the most enriched 
co-purified proteins, we detected SIN3A and SAP130, which have been previously identified 
to function as transcriptional regulators [48, 50]. Several members from the TRIP family 
including TRIP13 have been suggested to act as transcriptional co-regulators [85]. In lieu of 
this, we were interested to see whether TRIP13 along with its interaction partners of SIN3A 
and SAP130 might shed new light into the mechanistic workings of the tumour promoting 
function of TRIP13. 
To rule out the possibility of false positives arising from enriched hits in our MS analysis, we 
decided to perform further biochemical analysis to prove that SIN3A and SAP130 are indeed 
interaction partners of TRIP13. Previous attempts to perform a TRIP13-IP to pull down 
SIN3A, SAP130 as well as a SIN3A/SAP130-IP to pull down TRIP13 have been 
unsuccessful (data not shown). We decided to adopt another method called the Proximity 
ligation assay (PLA), which has been reported to be more sensitive and dynamic in detecting 
interaction partners vs the traditional co-IP method.    
To do this, we first performed an immunofluorescences staining to identify the intracellular 
localization of TRIP13, SIN3A and SAP130 (Fig. 3.7). We detected TRIP13 expression 
strongly in the perinuclear zone, ubiquitously in the cytoplasmic and weakly in the nuclei. 
SIN3A and SAP130 expression were strictly nuclei-localized, in line with published findings 
from other studies [48, 50].  
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Thereafter, we performed the PLA assay to validate an intracellular interaction between 
TRIP13 with SIN3A or SAP130 (Fig. 3.8) Antibodies derived from different species are 
needed in order for this PLA procedure to be able to detect interactions between 2 potential 
targets. In Fig. 3.8, TRIP13 antibodies derived from rabbit along with either SIN3A or 
SAP130 derived from goat was used during this assay to probe for potential interactions. 
Every single red fluorescence spot indicates a close proximity of < 40μm of interactions 
between these two proteins being probed for. For detailed description on this PLA procedure, 
please refer to methods in section 5.  
 
 
 
 
 
 
 
Fig. 3.7  Intracellular localization of TRIP13, SIN3A and SAP130 in 
HCC cells by confocal imaging 
Immunofluorescence staining for TRIP13, SIN3A and SAP130 reveals the 
cellular localization of these proteins respectively in HLF cell line. DAPI 
staining marks the cell nucleus. The fixing of cells in chamber slides and 
subsequent processing for immunofluorescence and confocal imaging is 
outlined in methods in section 5.  Scale bar: 50μm  
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As a positive control for this assay, SIN3A+SAP130 (interacting partners as previously 
published) have been probed to first verify that this assay is working optimally under the 
given conditions (top panel in Fig. 3.8).  As expected, the red fluorescence dots 
corresponding to interactions between SIN3A and SAP130 were localized mainly in the 
nucleus. PLA for TRIP13 and SIN3A interactions showed up mainly in the nucleus, with 
some faint red dots in the cytoplasm. In the PLA for TRIP13 and SAP130, interactions seem 
to be localized mainly to the perinuclear and cytoplasm, along with weak staining in the 
nucleus. Please refer to the discussions in section 4, where a possible shuttling of TRIP, 
SIN3A is discussed. In the negative controls of this PLA assay, where one of the 2 antibodies 
in a probed pair has been replaced either with a control rabbit or goat lgG antibody, minimum 
background staining was seen in the cytoplasm but not in the nucleus. In essence, we have 
been able to verify that MS-identified TRIP13 partners of SIN3A and SAP130 do indeed 
interact with TRIP13 in an independent experimental setup.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.8 Proximity ligation assay (PLA) to validate an intracellular 
interaction between TRIP13 with SIN3A or SAP130 that were previously 
identified via a MS screen. 
Confocal imaging has been performed on Huh7 cells being processed for PLA 
staining. In this PLA protocol, pairs of antibodies of different species have been 
used to probe for interactions between TRIP13 (Rabbit) and SIN3A (Goat) or 
TRIP13 (Rabbit) and SAP130 (Goat) with reference to methods section 5. 
Every red fluorescent spot indicates a close proximity (< 40 μm) interaction 
between two targets being probed for.  PLA staining for SIN3A+SAP130 
served as an internal positive control for interacting partners. Negative controls 
for this PLA staining are shown in the bottom panel where one of the antibodies 
in a probed pair has been replaced with either an unconjugated Goat IgG or 
Rabbit IgG antibody.  Scale bar: 50μm  
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3.3.2 Effects of TRIP13 and interaction partners of SIN3A/SAP130 in HCC cell 
proliferation 
To test the effects of TRIP13 along with SIN3A and SAP130 on HCC cell growth, we 
performed siRNA transfections whereby different combinations of specific siRNA were used 
and proliferation was thereafter monitored in Fig. 3.9A. Whilst cell proliferation was 
impaired in TRIP13 knockdown cells as previously seen, SIN3A or SAP130 knockdown 
alone had no effects on proliferation. Interestingly, the TRIP13 siRNA proliferation defect 
was restored upon combinatorial knockdown of either SIN3A or SAP130. Due to the similar 
growth restoring effect that SIN3A and SAP130 gene depletion both exert in TRIP13 
knockdown cells, we decided to focus only on SIN3A in future experiments (given that the 
functions of SAP130 has been ascribed mainly due to its direct binding to SIN3A as reviewed 
in introduction). 
 
Concomitantly knockdown of SIN3A reverses growth defect in TRIP13-depleted cells 
A separate experiment was thereafter performed to examine only the growth effects of a 
concomitant knockdown of TRIP13+SIN3A. A similar rescue in growth defect of TRIP13 
knock down cells was observed up to D6 post combinatory depletion of TRIP13+SIN3A 
(Fig. 3.9B). The cell growth results above were further reaffirmed by a BrdU incorporation 
assay performed (Fig. 3.9C), where a combined knockdown of TRIP13+SIN3A significantly 
restored cell proliferation from TRIP13-depleted cells.  
Thereafter, using the cell lysates from these HLF cells depleted either of TRIP13 or SIN3A 
or both, we determined apoptotic levels by measuring caspase 3/7 activities in these cells 
(Fig. 3.9D) The Caspase 3/7 levels as measured in Fig. 3.9D were in accordance to what has 
been previously observed for TRIP13-depleted cells, in comparison to these cells, 
TRIP13+SIN3A depleted cells had only half the amount of Caspase 3/7 levels. 
Next, we checked for the mRNA and protein expression of genes regulating proliferation by 
qPCR and western blotting from HLF cell lysates harvested from this experiment (Fig. 3.9). 
Remarkably, we noticed a significant depletion of a proto-oncogene c-MYC, on both the 
protein and the mRNA levels upon TRIP13 knockdown (Fig. 3.10A, B). With regards to the 
well described role of c-Myc as a master regulator during cell proliferation and its frequent 
overexpression in multiple cancers including HCC, it seems plausible that reduced c-MYC 
activity could account for an arrested cell growth upon TRIP13 knockdown in HLF cells 
(Fig. 3.9B, C). In line with this notion and reflecting its corresponding effects on cell 
proliferation, the depletion of c-MYC in TRIP13 knockdown cells were partially restored 
when SIN3A was concomitantly depleted (Fig. 3.10). Conversely, SIN3A knockdown alone 
had no effects on cell growth or c-MYC levels (Fig. 3.10A). In the combined knockdown 
group, only a marginal decrease in knockdown efficiency of TRIP13 (<5%) was seen as 
compared to the single TRIP13 siRNA knockdown group. This indicates that a restored cell 
growth and c-MYC activity after concomitantly depleting TRIP13 and SIN3A cannot be due 
to a reduced efficiency of TRIP13-depletion induced growth arrest in this case.    
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Fig. 3.9A - C  Concomitant KD of SIN3A or SAP130 rescues the 
proliferation defect exerted by TRIP13 depletion in HLF cells 
Transfections using siRNAs targeting either TRIP13 or SIN3A or SAP130, or 
both were performed. Cell proliferation are thereafter monitored up to D6 post 
transfection. Results from representative experiments were shown. (A) Growth 
rate of cells in 96-well plates D1 to D4 post transfection were measured by 
using CCK8 (cell counting kit 8), following protocols described in section 5. 
Absorbance at 450nm directly correlates to the number of viable cells in the 
well. (B) Growth rate of cells comparing siTRIP13 cells vs combined KD of 
TRIP13+SIN3A up to D6 post transfection. (C) Cell proliferation from 
combined siRNA KD was measured at D3 post transfection using a BrdU 
incorporation kit following protocols described in section 5. Values are shown 
normalized to that of the siNTC conditions    
Data are plotted as mean ± SEM. **** p≤ 0,0001; *** p≤ 0,001; **p≤ 0,01; 
vs siNTC determined by 2-way Anova. NS indicates not significant. 
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Fig. 3.9D   Apoptotic levels in HLF cells depleted either with TRIP13 or 
SIN3A or both 
HLF cells were harvested D3 post transfection and apoptosis were determined 
by measuring Caspase 3/7 levels from cell lysates using an assay kit: Glo-
caspase3/7 homogenous assay, following protocols in section 5. Fluorescence 
values for the amount of caspases3/7 levels present were plotted relative to the 
siNTC group. Data are plotted as mean ± SEM. **p≤ 0,01; ****p≤ 0,0001 vs 
siNTC or siTRIP13 as indicated in the chart and determined by 2-way Anova.  
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Thereafter, we performed at least four additionally experiments under the experimental set up 
as before and have always observed a corresponding rescue of TRIP13-depletion dependent 
growth defect upon simultaneous knockdown of SIN3A in HLF cells (cell growth are similar 
to    Fig. 3.9). A partial restoration of c-MYC and CyclinD1 in TRIP13+SIN3A conditions 
could similarly be seen from 3 of these independent experiments conducted in Fig. 3.11.  
Next, in order to determine whether cellular localization of TRIP13 and SIN3A changes upon   
single or combined gene knockdown, we performed cellular fractionation on these HLF cells, 
harvested D3 post transfection. In Fig. 3.12, TRIP13 expression was seen in both the 
cytoplasmic and nuclear fractions, whereas SIN3A was localized only to the nuclear fraction. 
No changes were however observed in the cellular localization of SIN3A upon TRIP13 
knockdown or vice versa in TRIP13 upon SIN3A knockdown. 
 In conclusion of the above findings, we have observed a robust restoration of cell 
proliferation and c-MYC levels during TRIP13-depletion when SIN3A was concomitantly 
inactivated in HLF cells. It is conceivable that a reduced c-MYC activity accounted for the 
severe proliferation defect along with a down regulation of growth promoting proteins like 
EGFR and CyclinD1 in TRIP13 inactivated HLF cells (Fig. 3.10)  
Fig.  3.10 Expression levels of TRIP13, SIN3A and c-MYC after 
combined siRNA transfection in HLF cells 
mRNA and protein expression levels D3 post transfection.  
(A) mRNA levels of TRIP13, SIN3A and c-MYC are normalized against TBP 
and shown as relative to the siNTC group.  (B) Blotting for SIN3A, EGFR 
TRIP13 and c-MYC with VCP as a loading control. Data are plotted as mean ± 
SEM. (A) **** p≤  0,0001; **p≤  0,01; vs siNTC determined by two-tailed 
welch’s t-test. (C) * p≤  0,05 ; vs siNTC determined by 2-way Anova. NS 
indicates not significant difference. 
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Fig. 3.11 Partial restoration of c-MYC and Cyclin D1 (CCND1) after 
concomitantly knockdown of TRIP13+SIN3A from 3 independent 
experiments 
Cell lysates were harvested D3 post transfection in HLF cells and blotted for c-
MYC and CCND1, with VCP as a loading control.  siRNA KD on protein 
levels for TRIP13 and SIN3A has been separately verified via western blot 
(data not shown). 
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Fig. 3.12 Cellular fractionation to determine cell localization of 
TRIP13 and SIN3A during single and combined knockdown of these genes 
Cell lysates were harvested D3 post transfection in HLF cells and blotted for 
SIN3A and TRIP13, with HSP90 and LaminA/C as a loading control for 
cytoplasmic and nuclear fractions respectively.  The loadings from the whole 
cell lysate, cytoplasmic and the nuclear fraction are shown.  
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3.3.3 SIN3A knockdown reverses the anti-proliferative effects from TRIP13-depletion 
and is recapitulated in several HCC cell lines 
In order to rule out a common experimental pitfall that our findings above were cell line-
specific only in HLF cells, we decided to include several other HCC cell lines namely human 
Huh7, HepG2 and mouse Hepa1-6 cells. In Fig. 3.13, we performed siRNA transfections to 
knockdown either TRIP13 or SIN3A or both and measured cell proliferation in these various 
cell lines as shown. In Huh7, HepG2 and Hepa1-6 cells, a concomitant knockdown of SIN3A 
partially restored cell growth in TRIP13-depleted cells from D3 onwards (Fig. 3.13A, B&C). 
These results above were also reaffirmed during a BrdU assay in Huh7 (Fig. 3.13D) cells. For 
Hepa1-6 in Fig. 3.13E, there were no effects on BrdU uptake across all samples as compared 
to the control group. This was in contrast with our previous results in Fig. 3.2 showing that an 
impaired cell proliferation during TRIP13-depletion in Hepa1-6 could be captured both via a 
CCK8 cell counting kit and the BrdU uptake assay. We assumed that a lack of changes in 
BrdU uptake even in the TRIP13 depleted cells could be due to the suboptimal knockdown 
efficiencies for Hepa1-6 in this experiment.  
Thereafter, we analysed the gene expression of c-MYC from these various cell lines upon 
single or combined depletion of TRIP13 and Sin3A (Fig. 3.14). A reduction of c-MYC 
protein levels in Huh7 cells across all samples upon depleting either TRIP13 or SIN3A or 
both was seen. The corresponding effect in the combined knockdown of TRIP13+SIN3A is 
unclear. The lower endogenous levels of c-MYC in Huh7 cells made it hard to ascertain 
whether there was indeed a partial restoration of c-MYC in this case. We observed also a 
depletion of c-MYC across all samples upon depleting either TRIP13 or SIN3A or both in 
Hepa1-6 cells. The restoration of c-MYC levels as seen previously in HLF cells (Fig. 3.11) 
was not seen in Hepa1-6 cells, where the c-MYC levels were lower in the combined 
knockdown of TRIP13+SIN3A vs the single gene knockdown. 
In summary, we were able to reverse the antiproliferative effects of TRIP13-depletion by 
concomitantly depleting SIN3A in various HCC cell lines of HLF, Huh7, HepG2 and Hepa1-
6 cells. The corresponding effect in restoring c-MYC levels during TRIP13-depletion, when 
SIN3A is concomitantly depleted is established in HLF cells. Due to the absence of a clear 
rescue of c-MYC levels in other cell lines, this effect could not be conclusively confirmed in 
other cell lines as tested. 
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Fig. 3.13 Concomitant KD of SIN3A rescues the growth defect in 
TRIP13-depleted human Huh7 and HepG2 but not mouse Hepa1-6 cells 
siRNA transfections to knockdown either TRIP13 or SIN3A or both was 
performed in Huh7, HepG2 and Hepa1-6 cells. Cell proliferation was monitored 
up to D4 post transfection. (A) Cell proliferation has been measured via a 
CCK8 kit (B) Cell proliferation has been measured via BrdU incorporation 
using a BrdU labelling kit Data are plotted as mean ± SEM. (A) *** p≤ 0,001; 
**p≤ 0,01) * p≤ 0,05 vs siTRIP13 determined by two-tailed welch’s t-test. (C) 
**** p≤  0,0001; vs siNTC determined by 2-way Anova. NS indicates non-
significant differences 
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3.3.4 The oncogenic c-MYC pathway in mediating antiproliferative effects upon 
TRIP13 depletion in HLF cells 
We first observed a marked reduction in c-MYC levels, along with several growth promoting 
factors like EGFR and cyclinD1 when we knock down TRIP13. In order to decipher the 
mechanistic framework in the oncogenic functions of TRIP13, we performed a MS analysis 
to identify interaction partners defining involved regulatory complexes (Fig. 1.10). Due to the 
initial hypothesis that TRIP13 might transcriptionally regulate EGFR mRNA levels, we 
decided to focus on this MS-enriched target, SIN3A, with well-characterised functions as a 
global transcriptional regulator. As shown from Fig. 3.9 to Fig. 3.11 in HLF cells, the 
decrease in growth and c-MYC levels upon TRIP13 ablation was strikingly reversed upon a 
concomitant ablation of SIN3A. Indeed, SIN3A forms part of the histone deacetylation 
complex (HDAC) and represses MYC activities by directly deacetylating and destabilizing c-
MYC [48]. 
In line with this, we wanted to test the idea that a reduction in c-MYC related activities 
accounted for the growth arrest along with a down regulation of growth promoting factors 
like EGFR and Cyclin D1 in TRIP13 inactivated cells (Fig. 3.10). To test this hypothesis that 
c-MYC could be an important mediator in conveying TRIP13-dependent effects on cell 
growth, we performed a gain of function analysis by overexpressing a full length human c-
MYC to observe for effects on cell proliferation thereafter (Fig. 3.15). 
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Fig. 3.14 Expression levels of c-MYC after depleting TRIP13 or 
SIN3A or both in Huh7 and Hepa1-6 cells 
Western blot was performed using cell lysates harvested D3 post siRNA 
transfection. Immunoblotting for SIN3A, TRIP13 and c-MYC was performed 
with VCP as a loading control.  
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Fig. 3.15 Overexpression of c-MYC rescues the proliferation defect in 
TRIP13 deficient HLF cells 
Co-transfections with siRNAs targeting against TRIP13, +/- a plasmid 
overexpressing full-length human c-MYC was performed in HLF cells.  Cell 
proliferation and western blot are shown. (A) Cell proliferation has been 
measured via a CCK8 kit using protocol from section 5. Abs at 450nm 
correlates directly to the number of cells in this assay. (B) Cell proliferation has 
been measured via BrdU incorporation using a BrdU labelling kit. (C) 
Immunoblotting for SIN3A, TRIP13 and c-MYC with VCP as a loading 
control.  Data are plotted as mean ± SEM. (A) **** p≤ 0,0001; **p≤ 0,01; vs 
siTRIP13 determined by two-tailed welch’s t-test. ## p≤ 0,01; #### p≤ 0,0001 
vs siNTC (B) ***p≤ 0,001; *p≤ 0,01 vs siNTC determined by 2-way Anova.  
HLF - Growth curve
D1 D2 D3 D4
0
1
2
3
4
Days post transfection
A
b
s
 4
5
0
n
m
siNTC
siNTC+
p-cMYC O/E
siTRIP13
siTRIP13+
p-cMYC O/E
****
****
**
##
##
####
Trip13  
VCP 
Sin3A  
c MYC 
s
iN
T
C
+
  
p
-c
M
Y
C
O
/E
 
s
iT
R
IP
1
3
+
  
p
-c
M
Y
C
 O
/E
 
s
iN
T
C
 
s
iT
R
IP
1
3
 
HLF - Cell proliferation 
si
N
TC
si
N
TC
+p
-c
M
Y
C
 O
/E
si
TR
IP
13
si
TR
IP
13
+p
-c
M
Y
C
 O
/E
0
1
2
3
4
B
rd
U
 u
p
ta
k
e
 
re
la
ti
v
e
 t
o
 N
T
C
*
****
*
A
C
B
 3  RESULTS 
 46 
 
HLF cells were co-transfected either with a plasmid overexpressing c-MYC (p-cMYC O/E), 
or an empty vector backbone along with NTC or TRIP13 targeted siRNAs. In Fig. 3.15A, 
TRIP13-depleted cells were expectedly growth arrested from D2 post gene knockdown. This 
growth arrest was remarkably reversed when a full-length c-MYC protein was concomitantly 
overexpressed in these TRIP13-depleted cells, resulting in an almost complete proliferation 
rescue at D3 and D4. This was similarly recapitulated in the BrdU uptake assay where 
concomitantly overexpressing c-MYC resulted in 4 times the amount of cell proliferation in 
TRIP13-depleted cells (Fig. 3.15B), nearly reaching control BrdU levels. On another note, 
the increase in BrdU uptake upon c-MYC overexpression in the si-Control group was not 
recapitulated in the growth curve via the CCK8 assay (Fig. 3.15A). Cell lysates from this 
experiment was subsequently harvested and immunoblotted to verify for TRIP13, c-MYC 
and SIN3A expression against VCP as the loading control (Fig. 3.15C). 
These results above are in line with our hypothesis that reduced c-MYC activities contribute 
towards the anti-proliferative effects of TRIP13-depleted HCC cells. Reflecting a central role 
that c-MYC plays in relaying the tumour-promoting function of TRIP13, we observed a 
complete rescue of growth arrest when c-MYC was simultaneously overexpressed in 
TRIP13-depleted cells. For further in-depth discussion with regards to this TRIP13-SIN3A-c-
MYC axis that we propose, please refer to discussions in section 4.   We hypothesize that the 
ability of SIN3A to exert a destabilizing effect on c-MYC depends on the absences of 
TRIP13. A SIN3A- dependent depletion of c-MYC is lifted when both TRIP13 and SIN3A 
were concomitantly depleted, as seen by the partial restoration of c-MYC levels in those cells 
in Fig. 3.11.  
 
3.3.5 Establishing stable cell lines with concomitant depletion of TRIP13 and SIN3A for 
in vivo tumour implantation models 
We aim to validate our hypothesis of a TRIP13-SIN3A-MYC axis in vivo in a tumour 
implantation model as outlined in Fig. 3.16A. In this approach, TRIP13 or SIN3A or both 
will be inactivated either in Human HLF or mouse Hepa1-6 cells using a lentivirus-mediated 
shRNA incorporation approach. Genetically modified cells would then be implanted either 
into immune-deficient mice (Human HLF cells) or C57Bl/6 mice (mouse Hepa1-6 cells). 
Tumour growth would be monitored and cell proliferation markers would thereafter be 
analysed at the end of the study from these tumour tissues.   
Numerous attempts in the past have failed to establish a stable knockdown of TRIP13 in 
HCC cells, due to a low cell viability post TRIP13 depletion. Using an alternative approach 
to circumvent this problem, we decided to first establish a stable knockdown of SIN3A in 
HLF and Hepa1-6 cells since depleting SIN3A conferred no effects on cell growth. One week 
prior to the tumour implantation study, these SIN3A-depleted stable cell lines would be 
infected with Lentiviral particles to mediate an shRNA dependent knockdown of TRIP13. 
After one round of antibiotics selection using blasticidin (SIN3A) and puromycin (TRIP13), 
these shTRIP13+shSIN3A-depleted cells would be directly implanted into the animals.  
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A set of 4 SIN3A-specific shRNA constructs, each containing a unique 29mer specifically 
targeting SIN3A was ordered from Origene. For the specific vector backbone and shRNA 
sequences of these 29mer, refer to materials in section 5. As the SIN3A shRNA vectors were 
available only in a pGFP-C-shLenti plasmid backbone that conferred a puromycin resistance 
gene (which was similar to that of the antibiotic resistance for TRIP13-shRNA expression 
vectors that we already have), we had to subclone these SIN3A-shRNA expression cassettes 
into another vector backbone of pRFP-C-shLenti that confers the blasticidin resistance gene 
(data not shown). 
After the sequences of the subcloned SIN3A-shRNA constructs have been verified via 
sequencing analysis, we then proceeded to package these constructs into the respective 
lentiviral particles using HEK293T cells. The efficiencies of each of these lentiviral-mediated 
knockdowns of SIN3A, 7-days post blasticidin selections in HLF and Hepa1-6 cells are as 
shown in Fig. 3.16B. Lentiviral particles containing shRNA constructs from shSIN3A_1 and 
shSIN3A_4 mediated the most efficient knockdowns in HLF and Hepa1-6 and were used 
subsequently to establish stable SIN3A knockdowns in these cell lines.  
Due to the lack of time, the initial aim to perform an in vivo tumour implantation study using 
shTRIP13+shSIN3A HCC cells could not be realized in time before the thesis was 
completed.  
 
 
Fig. 3.16A Planned tumour implantation study using 
shTRIP13+shSIN3A HCC cells 
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Fig. 3.16B  Generating stable HLF and Hepa1-6 cell lines with shR KD 
of SIN3A using a Lentiviral-mediated system 
Lentivirus containing plasmid with different shRNA sequence targeting against 
SIN3A are denoted as shSIN3A_1, shSIN3A_3 and shSIN3A_4. Lentivirus 
production and quantification was outlined in methods in section 5.  Lentivirus 
was added to cells at an MOI of 10 along with polybrene (8 mg/ml) to enhance 
the virus transduction. D5 post-viral transduction, Blasticidin at (2 mg/ml) was 
added to select for resistant cells that are successfully expressing the pLKO-
shRSIN3A plasmids.  Western blot shows SIN3A expression in different cell 
lines D7 post blasticidin selection, using VCP as a loading control.  
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3.4 Effects of overexpressing Trip13 in non-tumourigenic AML12 liver 
cells 
3.4.1 Overexpressing Trip13 in AML12 cells boosted an increase in cell proliferation  
As shown in the Fig. 1.5, Trip13 was upregulated in various fatty liver-related disease 
conditions in ob/ob, db/db and high fat diet fed mice as well as in a mouse model of non-
alcoholic steatohepatitis (NASH) upon methionine-choline deficient diet feeding.    
Furthermore, numerous reports have shown TRIP13 to be significantly upregulated in various 
types of cancer including liver cancer (from our own data). We have also provided in vivo 
and in vitro data indicating that TRIP13 plays a central role in oncogenic growth of liver 
cancer cells.  
AML12 is a non-transformed mouse liver cell line, derived from a mouse transgenic for 
human TGFα, allowing it to be continuously passaged in cell culture. We have separately 
verified that the expression levels of Trip13 in AML12 to be at least 4 times lower than that 
in HCC cell lines of HLF and Huh7, based on mRNA expression analysis (data not shown). 
Under this premise, we were interested to investigate if overexpressing Trip13 could 
contribute to oncogenic transformation of AML12 cells.  
Overexpressing a full-length mouse Trip13 in AMl12 cells resulted in a significant induction 
in cell growth, 3 days upon Trip13 overexpression (Fig. 3.17A). This increase in cell growth 
was similarly reflected in the BrdU uptake assay in Fig. 3.16B, where Trip13 overexpressing 
cells showed 1,5 fold increase in proliferation vs the control cells. In line with the growth 
promoting effects, western analysis for different tumourigenic factors like EGFR, c-MYC 
and p-53 showed all these proteins to be upregulated in the Trip13 overexpressing AML12 vs 
the control cells (Fig. 3.16C). On a separate note, an overexpression of a full length human 
TRIP13 in a HepG2 liver cancer cell line did not showed any significant effects on cell 
growth, BrdU uptake and c-MYC levels (Fig. 3.16D, E, F). We were unsuccessful after 
numerous attempts to perform the Colony forming assays for AML12 to compare 
tumourigenicity between Trip13 overexpressing vs control cells. These cells were deemed to 
be unsuitable for this colony assay in our hands, due to the low cell viability (when AML12 
cells were seeded at a low density to perform this assay) and inability to form viable colonies. 
In view of the above, we have further highlighted the pro-tumourigenic function of TRIP13 
by demonstrating that an overexpression of this gene is sufficient to stimulate cell 
proliferation in a non-tumourigenic hepatocyte cell line of AML12. This induction in cell 
proliferation is further reflected by a corresponding upregulation of growth promoting factors 
like EGFR and c-Myc.  
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Fig. 3.17 Overexpression of TRIP13 resulted in an increase in cell 
proliferation in non-tumourigenic AMl12 cells but not in HepG2 cells 
Transfections using plasmids overexpressing either a full-length human or 
mouse TRIP13 was performed in HepG2 or AML12 cells respectively. (A) Cell 
proliferation has been measured via a CCK8 kit. Abs at 450nm correlates 
directly to the number of cells in this assay. (B) Cell proliferation has been 
measured via BrdU incorporation using a BrdU labelling kit on D3 post 
transfection. (C) Blotting for EGFR, p-53, TRIP13 and c-MYC with HSP90 as 
a loading control.  Data are plotted as mean ± SEM. **** p≤ 0,0001; ***p≤ 
0,001; *p ≤  0,01 vs pcDNA3.1 determined by 2-tailed Welch’s t-test. N.S 
indicates non significant differences 
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3.5 Role of TRIP13 in the DNA damage repair pathway 
3.5.1 Chromosomal instability (CIN) and upstream regulation of TRIP13 
Chromosomal instability is a phenomenon commonly seen in tumour cells when 
chromosomes are improperly segregated in daughter cells due to the loss of proper 
checkpoint controls. In this regard, a CIN signature refers to a specific set of highly ranked 
genes that is consistently correlated with chromosomal instability in cancer. The Hippo/YAP 
signalling was found to be one of the main drivers in regulating the expression of the CIN 
signature genes in liver cancer, with TRIP13 being found to be one of the 25 top ranking 
genes (reviewed in section 2.2.2). In a mouse model for HCC, it was found that 
overexpressing YAP stimulated both invasiveness and growth of tumour cells. Furthermore, 
liver cancer patients with tumour gene expression pattern associated with the CIN signature 
were characterized by a poorer prognosis [39].   
In this context, it seems possible that YAP could be an upstream regulator of TRIP13, where 
an upregulation of the hippo/YAP signalling mediates a corresponding increase in TRIP13 as 
commonly seen in human HCC patients. We picture that knocking down YAP could result in 
a corresponding decrease in TRIP13 along with its downstream targets in HCC cells.  
To test this hypothesis, we performed a loss of function analysis by knocking down YAP1 
using target specific siRNA. As shown in Fig. 3.18A & B, a knockdown of YAP1 resulted in 
a corresponding decrease in expression of TRIP13 along with EGFR, in both HLF and Huh7 
cells. This decrease in mRNA expression levels of TRIP13 and EGFR was similarly 
recapitulated on the protein levels via western blot analysis in Fig. 3.17C. In Huh7 cells (Fig. 
3.18B), the knockdown of YAP1 resulted in an almost complete depletion of YAP1, which 
might account for the marked decrease in a corresponding expression of TRIP13 and EGFR 
(vs the less dramatic effects in HLF cells). These results seen above suggest that YAP could 
indeed be an upstream regulator of TRIP13 in HCC cells. 
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3.5.2 TRIP13 in DNA damage repair pathways 
TRIP13 has been described in several reports [34, 35, 45] to be indispensible during DNA 
damage repair and non-homologous end joining (NHEJ). Furthermore, the role of TRIP13 
during NHEJ was proposed to be the main oncogenic mechanism in conferring chemo-
resistances to head and neck tumour cells [45]. Owning to the enhanced DNA repair 
machinery of these TRIP13-overexpressing tumour cells, these cells acquire resistances 
against the genotoxins commonly used in chemotherapeutic treatments [45]. 
 We were similarly interested to explore the DNA damage repair role of TRIP13 and more 
importantly whether this pathway when deregulated attributed to the severe growth defect in 
TRIP13 depleted HCC cells.  D3 post TRIP13 depletion, DNA fragmentation was 
characterized by grossly abnormal nuclear morphology and nuclear blebbing in Fig. 3.19A.  
Fig. 3.18 YAP as a plausible upstream regulator of TRIP13 
siRNAs targeting against YAP1 was performed in HLF and Huh7 cells.  mRNA 
and protein expression has been performed on cells harvested D3 post 
transfection. (A) mRNA expression of YAP, TRIP13 and EGFR were 
normalized against TBP and represented relative to the NTC group. (B) Blotting 
for EGFR, YAP, and TRIP13 with HSP90 as a loading control.  Data are 
plotted as mean ± SEM. **** p≤ 0,0001; **p≤ 0,001 vs siNTC determined by 
2-tailed Welch’s test.  
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pH2AXγ, which is a marker to detect for DNA damage was also remarkably upregulated in 
these TRIP13-depleted HLF cells (Fig. 3.19B). Reflecting what was seen above, the caspase 
3/7 levels in these TRIP13-depleted cells were 38 folds more than that of the control group in 
Fig. 3.19C. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.19 A– C      TRIP13 depletion triggered an increase in DNA damage  
Confocal images of siNTC vs siTRIP13 HLF cells are shown. Cell lysates were 
harvested for western blotting and separately measured for caspase 3/7 levels. 
(A) Immunofluorescence staining of DAPI and TRIP13 are compared between 
siNTC vs sTRIP13 cells. (B) Western Blotting for TRIP13 and p-H2AXy with 
VCP as a loading control. (C) Caspase 3/7 levels has been measured from cell 
lysates using this assay kit: Glo-caspase3/7 homogenous assay, following 
protocol of section 5. Fluorescence values for the amount of caspases3/7 present 
were plotted relative to the siNTC group. Scale bar indicates 50um. Data are 
plotted as mean ± SEM. **p≤ 0,001 vs siNTC determined by 2-tailed Welch’s 
test.  
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3.5.3 DNA damage signalling pathway does not play a central role in causing 
proliferation defect in TRIP13-KD cells 
 Our data thus far suggests that TRIP13 could be part of an oncogenic signalling network, 
regulating downstream c-MYC activities, which could indeed play a central role in HCC 
tumourigenesis. In lieu of this hypothesis above, one has to also consider several other 
aspects of oncogenic regulation that determines the final outcome between cell survival vs 
cell death. In this respect, we questioned whether the role that TRIP13 plays during DDR 
could also have a central role in determining the oncogenic growth of HCC cells.  
KU60019 is an ATM (Ataxia Telangiectasia Mutated Protein) inhibitor that is used 
frequently to block the central DNA damage response  (DDR) mediated via ATM signalling. 
In this experiment, we treated HLF cells in a final concentration of 3 μM of KU60019 to 
observe for a possible effect on cell growth between the control vs TRIP13-depleted cells in   
Fig. 3.19D. TRIP13-depleted cells were expectedly growth arrested D2 upon gene depletion. 
Importantly, we observed that an inhibition of the DDR pathway via ATM signalling 
(+KU60019) did not reverse the growth defect in these TRIP13-depleted cells. If an 
accumulation of DNA damage due to TRIP13 depletion were mainly responsible for the 
growth arrest in TRIP13-depleted HCC cells, then a reversal of this growth defect would 
have occurred when this DDR pathway was inhibited which was not the case in Fig. 3.19D. 
In light of the above findings, we argue that the DNA damage repair role of TRIP13 is no 
doubt an important aspect during tumourigenesis; it was however not a main attributor in 
inhibiting proliferation as seen upon TRIP13 knockdown in HCC cells. 
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Fig. 3.19D Growth defect in TRIP13-depleted cells are not dependent on 
the ATM DNA damage pathway  
Growth of HLF cells +/- an ATM inhibitor (KU60019) was compared between 
the siNTC vs siTRIP13 group. One day post siRNA transfections, KU60019 
was added at a final concentration of 30 μM to the respective wells. Fresh 
media +/- KU60019 was given to cells and cell growth was assessed with the 
CCK8 kit. The absorbance at 450nm correlates directly to the cell numbers. 
Data are plotted as mean ± SEM. **p≤ 0,001 vs siNTC determined by 2-tailed 
Welch’s test. NS indicates non-significant difference between siTRIP13+/- 
KU60019. 
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3.5.3 DNA damage persist despite a growth rescue during concomitant depletion of 
TRIP13+SIN3A  
As previously seen in Fig. 3.9 and Fig. 3.11, growth arrest in TRIP13-depletd cells could be 
reversed by concomitantly depleting SIN3A in multiple HCC cell lines. We were curious to 
examine also the DNA damage levels in these “growth rescued” cells as compared to the 
TRIP13-depleted cells alone. 
 In Fig. 3.20A, we observed a marked accumulation of p-γH2AX in the nucleus of TRIP13-
depleted cells as compared to the control cells D3 post gene-depletion. In the bottom panel of 
Fig. 3.20A, despite an apparent growth rescue of cells by a concomitant depletion of 
TRIP13+SIN3A, these cells continue to accumulate high levels of p-γH2AX. As a side note, 
as images were captured on a random field of view, the number of cells in the images are 
non-representative of the true total amount of cells in that sample.  Similar to what was 
observed on the immunofluorescence (IF) staining for p-γH2AX, we observed an 
upregulation of this DNA damage marker in both TRIP13 depleted and TRIP13+SIN3A 
depleted cells in Fig. 3.20B. No changes in the level of p-γH2AX in SIN3A-depleted cells 
were observed (data not shown).  
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Fig. 3.20A Accumulation of DNA damage in combined 
siTRIP13+SIN3A persisted in spite of a growth rescue   
HLF cells were transfected with siNTC, siTRIP13 or siTRIP13+SIN3A, using 
siNTC for titrations to an equal final amount during transfection. D1 post 
siRNA transfections, cells were seeded into chamber slides for further 
incubation before being harvested for immunofluorescences (IF) staining D3 
post transfection. IF was performed in reference to methods in section 5. 
Confocal images shows IF staining for DAPI and p-γH2AX from the different 
siRNA conditions. Scale bar indicates 50 μm. 
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As a summary to conclude what has been observed thus far, a reversal of growth arrest is 
seen in TRIP13-depleted cells upon concomitant knockdown of SIN3A. Interestingly, 
proliferation in these cells was apparently not impaired by an accumulation of DNA 
fragmentation as seen via an upregulation of p-γH2AX unlike the corresponding growth 
arrest in TRIP13-depleted cells. In lieu of the above findings, it is unlikely that an 
accumulation of DNA damage could have accounted for the severe growth arrest in TRIP13-
depleted cells. This proliferation impairment could have been caused by a deregulated 
oncogenic signalling pathway, in this case the c-MYC proto-oncogene, which when 
overexpressed was able to reverse the growth arrest in TRIP13-depleted HLF cells.  
 
 
Fig. 3.20B   Detection of DNA-damage markers in HLF cells depleted 
either with TRIP13 or SIN3A or both 
HLF cells were harvested D3 post transfection for western blotting to deter for 
DNA damage.  Immunoblotting was performed for TRIP13 and p-γH2AX with 
VCP as a loading control.  
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4 Discussions 
 
4.1 TRIP13 as an oncogenic regulator of tumour growth 
 
4.1.1 TRIP13 in cell cycle checkpoint and cancer 
 
TRIP13 was first identified as a novel transcriptional co-regulator that binds to the 
Thyroid hormone receptor (TR), both in the presence or absence of Thyroid hormones (TH) 
[85]. Early studies of the conserved mammalian orthologue of Trip13 in budding yeast cell; 
C-elegans and Drosophila have discovered an essential role of this factor in regulating 
chromosomal events during meiosis and mitotic progression [25, 26]. Functional roles of 
Trip3 in meiotic recombination dates back to its activating roles in double strand-break 
(DSB) checkpoint responses and in establishing inter-homologous recombination (HR) 
during chromosome synapsis [27, 87]. Mammalian Trip13 was found to be involved in both 
the activation and silencing of the spindle assembly checkpoint (SAC) during mitotic 
progression [34].  
Intriguingly, TRIP13 was observed to be upregulated in a variety of human cancers, 
ranging from breast cancer, squamous cell carcinoma of head and neck (SCCHN), prostate 
cancer, non-small cell lung cancer and leukaemia [28, 37, 43, 45, 84]. The oncogenic 
properties of TRIP13 were recently investigated in breast cancer and SCCHN, where the 
upregulated expression of TRIP13 stimulated growth and cell invasiveness of these tumour 
cells [45, 28]. Furthermore, the ability of treatment-resistant SCC cells to escape cell death 
was proposed to be due to the enhanced ability of such high-TRIP13 expressing cells in 
repairing DNA damage induced during chemotherapy [45]. Besides this aforementioned 
DNA-repairing role of TRIP13 in conferring surviving advantages to tumour cells during 
genotoxic assaults, the underlying molecular and cellular mechanisms of TRIP13 in 
mediating a pro-proliferative effect during tumourigenesis is largely unclear. 
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4.1.2 A proliferation-promoting role of TRIP13 in liver cancer 
The present study is the first to have confirmed an oncogenic role of TRIP13 in 
hepatocellular carcinoma (HCC). Through various in vivo tumour xenograft models and 
established in vitro systems of HCC cell lines, we have established the following findings: 
Firstly, TRIP13 is essential during hepatocyte regeneration and HCC cell proliferation, 
without which, cell proliferation is impaired. Secondly, we identified novel interaction 
partners of TRIP13 via a MS screening, which has shed new light into the proliferative roles 
of TRIP13 in section 3.3. Thirdly, we demonstrated that the proliferation impairment during 
TRIP13-depletion was not attributable to an upregulation of the DNA-damage response 
(DDR) pathway in section 3.5. Lastly, we have data to suggest the mechanistic regulations, 
both upstream and downstream of TRIP13 in section 3.2, 3.3 and 3.5. Our findings confirm 
previous aforementioned publications regarding the oncogenic role TRIP13 whilst providing 
a functional annotation and unveiling the mechanistic involvements of TRIP13 during 
tumourigenesis.  
We have previously shown that overexpressing Trip13 in a non-transformed liver cell 
line, AML12, stimulated cell proliferation in those cells (Fig. 3.16). Further along this line, 
an upregulation of oncogenic factors like C-MYC, EGFR was observed (Fig. 3.16). 
Interestingly, overexpressing TRIP13 in several human HCC cell lines did not produce this 
pro-proliferative effect as seen in AML12 cells. We speculate that these HCC cells could 
have been non-responsive to a further increase in TRIP13 levels, due to already high 
endogenous levels of TRIP13. Under this pre-text of a high TRIP13-driven proliferative 
growth in these HCC cells, simply increasing TRIP13 independently of other oncogenic 
factors would not further stimulate proliferation in these tumour cells. Conversely in AML12 
cells, where the endogenous Trip13 levels are much lower compared to HCC cells, 
overexpressing Trip13 could stimulate proliferation via activation of growth-promoting 
pathways which is synonymous with what we have observed. It remains to be seen whether 
overexpressing TRIP13 in a HCC cell line with low endogenous levels of TRIP13 would  
similarly stimulate cell proliferation as in AML12 cells.  
 
 
4.2 The functional implications of an interaction between TRIP13 and its 
interaction partner, SIN3A 
 
4.2.1 Validating an interaction between TRIP13 and interaction partners 
TRIP13 is a member of the highly conserved family of AAA
+
ATPases that are known 
to mediate diverse cellular activities. Through its ability to mediate protein-protein and 
protein-DNA complex assembly and disassembly, members from this ATPase family have 
been implicated in regulating diverse functions including cell signalling and cell cycling [24]. 
In order to investigate the mechanism through which TRIP13 exerts an oncogenic effect in 
liver cancer, we decided to perform a mass spectrometry screening to identify novel  
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interacting partners of TRIP13 (Fig. 1.10). Endogenous TRIP13 was immunoprecipitated 
from both HLF and Huh7 cells using TRIP13-specific antibodies. Based on KEGG pathway 
analysis, some of enriched pathways identified were cell cycle regulation, transcriptional co-
regulation and DNA damage repair pathways. 
TRIP13 could act as a transcriptional co-regulator in binding to TR as suggested by 
early studies [85] and from our own observations; TRIP13 seems to regulate the expression 
of EGFR.  Based on these early hypotheses that TRIP13 might function as a transcriptional 
co-regulator, we decided to focus on 2 candidates that were enriched from the MS screen, 
SIN3A and SAP130. These proteins have been well characterized as transcriptional 
regulators in forming part of the histone deacetylase complex (HDAC) during transcriptional 
repression [48, 50].  
We sought to independently perform co-IP to re-confirm a protein interaction between 
TRIP13 and its MS-identified interaction partners. Despite numerous attempts and optimizing 
Co-IP protocols, a pull down of Sin3A and SAP130 could not be captured from TRIP13-IP 
from HCC cells lines. There could be several biological and technical reasons as to why a co-
IP did not work in here. One feasible biological theory could be that a transient interaction 
between TRIP13+SIN3A/ SAP130 could be taking place at a specific cell cycle phase for 
instance in the M –phase where assembly and disassembly of mitotic complexes have been 
known to mediate this tightly orchestrated process. In light of this hypothesis, by 
synchronizing cells in specific cell cycle phases, we might be able to capture this transient 
interaction between TRIP13+SIN3A/ SAP130. As an evidence to back up this theory, we 
have seen an enrichment of interactions between TRIP13 and SIN3A or SAP130 in the 
nucleus and in mitotic cells undergoing various phases in the M-phase during PLA (Fig. 3.8). 
At a higher magnification of the PLA images, these interaction signals seem to be localized 
around the chromosomes in mitotic cells. Using fluorescent immunocytochemistry, we have 
verified that TRIP13 is predominantly localized in the cytoplasm and around the perinuclear 
region, whilst SIN3A and SAP130 are strictly nucleus- bound (Fig. 3.7). Although we were 
not able to confirm a transcriptional co-regulatory function of TRIP13, our above findings 
seem to suggest a checkpoint-related function resulting from an interaction between TRIP13 
and SIN3A/SAP130. 
In one study looking at the recovery of renal epithelial cells following acute kidney 
injury, the authors showed that TRIP13 played a fundamental role in the recovery phase of 
these damaged cells by modulating p53 activity via its interaction with a p53 cofactor, 
Tetratricopeptide domain 5 (TTCP5) [88]. Under normal basal conditions, TTCP5 was 
predominantly in the nucleus whilst TRIP13 was mainly in the cytoplasm. Under sublethal 
dose of H2O2, TRIP13 was detected also in the nucleus via an importin α/β-independent 
pathway.  Furthermore, an overexpression of TRIP13 with TTCP5 resulted in a redistribution 
of TRIP13 into the nucleus along with a decrease of p53 induction in the nucleus [88]. The 
shuttling of TRIP13 into the nucleus during an interaction with SIN3A/SAP130 might be in 
agreement with our PLA results in Fig. 3.8. It would be interesting to test whether there is 
indeed a shuttling of TRIP13 between the cytoplasm and nucleus in response to the following 
scenarios: an acute hepatic stress injury (eg. Partial Hepatectomy), chronic stress like the  
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administration of heptotoxins (eg. Tetrachloride CCL4, which does not induce genotoxic) or 
in response to an overexpression of interactions partners of SIN3A/SAP130.  
 
4.2.2 Depleting of SIN3A reverses the growth impairment of TRIP13-depleted cells  
TRIP13 expression is upregulated in several different kinds of cancers; however the 
functional annotations of its pro-proliferative roles are still unclear. The cancer related roles 
of SIN3A are similarly controversial due to its role as an oncogene in breast cancer whilst 
being separately reported to act as an antagonist against the proto-oncogene c-MYC [53-56]. 
We were curious to investigate the biological relevance of an interaction between TRIP13 
and its interaction partners of SIN3A and SAP130 in the context of liver cancer.  Much to our 
surprise, we observed a stark rescue in the proliferation defect of siTRIP13 KD cells when 
we concomitantly depleted SIN3A or SAP130 (Fig. 3.9). Due to the overlapping functions of 
SAP130 ascribed mainly via its binding to SIN3A, we decided to focus on SIN3A in order to 
reduce the complexities during further experiments. What was remarkable in these cells that 
were depleted of both TRIP13 and SIN3A was that the DNA damage marker, p-γH2AX 
remained high (marginally less than TRIP13-KD cells), whilst these cells appeared 
phenotypically normal with almost no signs of DNA fragmentation when counter-stained 
with DAPI (Fig. 3.20). This was in stark contrast against the DNA-damage response 
consistently observed during TRIP13 depletion, not only in our context of liver cancer but 
also in other cellular systems for instance in head and neck cancer, breast cancer and during 
ischemia injury of the kidney [88, 45, 28].  
In this scenario, we imagine an antagonistic interaction between TRIP13 and SIN3A 
on an unknown master regulator that plays a central role in signalling output. Under this 
regulator, cells are either committed for recovery or to progress towards cell death in 
response to severe DNA damage. A downregulation of growth promoting factors like c-
MYC, EGFR and downstream targets of the mTOR-signalling pathway (Fig. 1.9; Fig. 3.10) 
in TRIP13-depleted cells was reversed when both TRIP13 and SIN3A were concomitantly 
depleted. The relevance of these pathways in accounting for the reversal of proliferation 
defect in double KD of TRIP13+SIN3A are being discussed in the next sections below.  
Recently, fundamental questions regarding how TRIP13 recognizes and remodels its 
target-substrate/complexes has been unveiled in some studies. Through X-crystallography, it 
was demonstrated that the N-terminal domain (NTD) of TRIP13 is responsible for the 
binding of substrates or adaptors, for instance p31
comet
, which acts together with TRIP13 in 
silencing the mitotic checkpoint complex (MCC) [63]. In head and neck cancer, the ATPase 
domain of TRIP13 has been demonstrated to be vital in conferring its oncogenic properties 
during tumour growth [45]. In lieu of these findings, it would be of interest to use site-
directed mutagenesis to generate mutants in the NTD and/or ATPase domain of TRIP13 to 
probe for domain-interactions with SIN3A and downstream targets or pathways that would 
be altered. These results would be informative in providing more mechanistic basis for the 
interactions between TRIP13 and SIN3A and how this in turn translates to our observation of 
growth revival of HCC cells upon depletion of both factors.  
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4.3 Role of the oncogene c-Myc in liver cancer 
 
The proto-oncogene c-MYC is a ubiquitous transcription factor that regulates 
important aspects of biological functions including cell cycle progression, DNA replication, 
cell proliferation, growth, differentiation and apoptosis [97-99]. c-MYC is frequently 
upregulated not only throughout the progression of liver carcinogenesis but recently also 
implicated with chronic liver disease like alcoholic liver diseases,  viral hepatitis and liver 
fibrosis/cirrhosis [100]. Through the use of various experimental murine models of HCC 
including transgenic mouse models overexpressing c-MYC, this proto-oncogene has been 
demonstrated to be essential in HCC development [reviewed in 100]. Studies with c-MYC 
are of great clinical interest as high c-MYC levels along with p53 inactivation are an 
indicator for poor prognosis and early cancer recurrence in HCC patients [74,101].  
 
4.3.1 Possible cross talk between TRIP13 and c-MYC signalling pathways? 
Given the importance of c-MYC during liver regeneration and HCC tumourigenesis, 
we were intrigued by the possibility that c-MYC inactivation might account for the 
proliferative arrest and massive cell apoptosis upon TRIP13-depletion (Fig. 3.10). The 
decrease in c-MYC expression and its downstream target Cyclin D1 (CCND1) were 
consistently decreased in HLF and Huh7 cells upon TRIP13 KD. Interestingly, there was a 
partial restoration of the c-MYC levels, which coincided with the revival of cell proliferation 
when being depleted of both TRIP13 and SIN3A (Fig. 3.10).  
In order to test for the relevance of the c-MYC oncogene in here, we overexpressed 
(OE) a full-length human c-MYC protein and observed a partial rescue of growth defect and 
decrease in cell death in TRIP13-depleted cells (Fig. 3.15). Given that TRIP13-depleted cells 
were arrested in G2 phase of cell cycle, it would be informative to study the cell cycle profile 
of these TRIP13 KD cells that are growth revived upon OE of c-MYC. These findings 
support the hypothesis that a deregulation of c-MYC and its target genes might have resulted 
in changes in important cellular outcomes in terms of cell viability and proliferation as seen 
in cells depleted of TRIP13 or SIN3A or both.  
c-MYC has been described to be essential during hepatocyte regeneration after partial 
hepatectomy (PHX), it would be interesting to explore a possible interaction or cross talk 
between c-MYC and TRIP13 during proliferation under this context. As shown previously, 
TRIP13-depleted livers were significantly impaired during hepatocyte regeneration after 
PHX (Fig. 1.6). Further experiments to investigate if overexpressing c-MYC could rescue the 
regenerative defect of TRIP13-depleted livers after PHX will allow us to examine for a 
possible cross talk between TRIP13 and c-MYC. Concurrently, an overexpression of TRIP13 
with or without the co-expression of c-MYC during PHX and in mice models for HCC would 
be definitely insightful to probe for this possible cross talk. 
Due to the central role that c-MYC plays in regulating various aspects of cellular 
functions and in cancer, it is hardly surprising that an altered expression of this oncogene 
leads to deregulation of a large number of target genes that are consequently essential during  
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tumour growth. In order to look for novel Myc target genes during lymphomagenesis, 
Marinkovic, D.et al [89] used murine B and T lymphoma cells line that has been transformed 
with a conditional Myc-allele [89]. True indeed, the list of Myc target genes as identified via 
microarray analysis revealed essential functions ranging from cell proliferation, 
differentiation, signalling, metabolism, and protein synthesis to DNA repair [89]. Trip13 was 
found to be one of the 88 Myc-target genes in this list and was being categorized under the 
function of cell signalling [89].  We have separately verified from a “Champion ChIP 
transcription factor search portal” that TRIP13 contains 2 c-MYC binding sites (E-boxes 
sequences) in its 5’UTR promoter region. Recently in 2017, TRIP13 was identified to be an 
oncogenic factor in human chronic lymphocytic leukemia (CLL) [84]. The authors further 
proposed that c-MYC promotes TRIP13 expression by directly upregulating its 
transcriptional activities in CLL cells [84].  
 
4.3.2 A possible TRIP13- c-MYC-SIN3A axis in HCC? 
Coming back to our findings in the context of HCC, we do not exclude the possibility 
that the relationship between TRIP13 and c-MYC could indeed be acting bidirectional. In 
terms of transcriptional regulation, an overexpression of c-MYC commonly seen in liver 
tumours could well result in a transcriptional activation and upregulation of TRIP13 in 
tumour cells. On the other hand, the depletion of c-MYC consistently seen in TRIP13-
depleted HCC cells suggests that TRIP13 could similarly act in a feed-forward loop in here to 
maintain c-MYC expression in oncogenic cells. In addition to the above, there exist also the 
possibilities that the relationship/interaction between TRIP13 and c-MYC is mediated 
indirectly via other interacting factors or complex assembly.  It is well appreciated that Myc 
possess a large interactome, where Myc can be recruited through protein-protein interactions 
to the promoters of specific gene targets [90] whilst the recruitment of different effectors has 
been shown to affect the protein stability of Myc itself [90, 91]. Chromatin-
immunoprecipitation (ChIP) and dual luciferase reporter assays should be performed in order 
to test for this possible transcriptional regulatory relation between TRIP13 and c-MYC. 
SIN3A has been originally identified to be a co-repressor, associated to Myc-
antagonist of Mad-Max heterodimer in inhibiting Myc target activities [53-55]. The 
recruitment of the Sin3A/HDAC complex was shown to directly antagonize c-Myc activity 
via deacetylation and destabilization of the c-Myc protein [54, 92]. In light of we have 
observed, where there is a partial restoration of c-MYC and cell proliferation of TRIP13-
depleted cells upon simultaneous deletion of SIN3A, it seems plausible that TRIP13 and 
SIN3A exert opposing effects on c-MYC activity. SIN3A depletion alone results in no 
observable decrease in cell proliferation or c-MYC levels, suggesting that the ability of 
SIN3A to exert its destabilizing effects on c-MYC depends on the absence of TRIP13. In this 
model, we speculate that the interaction between TRIP13-SIN3A prevents SIN3A from 
complex formation with HDAC associated co-factors and subsequent deacetylation and 
degradation of c-MYC. TRIP13 depletion releases SIN3A to exert its repressive effects on c-
MYC, resulting in inhibition of c-MYC activities like cell growth, proliferation and  
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expression of growth related factors like EGFR and Cyclin D1.  Further studies to investigate 
whether an overexpression of SIN3A in the presence/absence of TRIP13 would affect the de-
acetylation levels and stability of c-MYC; along with promoter assay of c-MYC or c-MYC 
target genes would be necessary to reveal this functional relevance of a cross talk between 
TRIP13-SIN3A and c-MYC. Alternatively, overexpressing a c-MYC mutant (expressing a 
mimic of constitutive-acetylation for instance by replacing lysine with glutamine) would also 
allow us to test the functional relationship between TRIP13 and SIN3A and the consequent 
effects on c-MYC activities.   
 
4.4 The relevance of EGFR signalling pathway during liver homeostasis 
and tumourigenesis 
Several losses of function studies have highlighted the important role of EGFR during 
liver regeneration after partial hepatectomy (PHX). In these studies using mice with 
hepatocyte-specific knockout or expression of a dominant negative mutant version of EGFR, 
an impairment of hepatocyte proliferation upon acute liver injury or after PHX were 
consistently reported [93, 94, 95].  In human HCC, overexpression of EGFR occurs in more 
than 68% of patients being detected with aggressive tumours, metastasis, and poor clinical 
outcomes [102-104].  
We first observed a remarkable decrease in EGF receptor and receptor activation 
(EGF stimulation) across all HCC cells lines being investigated during TRIP13 depletion 
(Fig. 3.3). Concomitantly, a decrease in activation/phosphorylation of key factors along the 
mTOR-signalling pathway with the likes of S6K, eIF4B, 4E-BP1, cyclin D1 was seen. EGFR 
dual luciferase reporter assay further suggested that EGFR expressions could have been 
regulated by TRIP13 (Fig. 3.4). The preliminary conclusion that we first drawn were that the 
decrease in EGF-mTOR signalling could have been responsible for the proliferation defect 
seen during TRIP13-depletion. To investigate this, we decided to first test for the functional 
relevance of EGFR in HCC cells. Much to our dismay, a siRNA-mediated depletion of EGFR 
resulted only in a minor proliferation defect in HCC cells (Fig. 3.5). These minimal effects 
question the hypothesis that the EGFR signalling pathway plays a central role in regulating 
cell proliferation under our framework with TRIP13. Further pointing us away from this 
direction was the fact that EGFR expression was not upregulated in an expression array from 
a cohort of HCC patients in Heidelberg (Fig. 3.6). The overexpression of TRIP13 was 
nonetheless detected across all samples from CLD and HCC patients where we then saw a 
negative correlation between TRIP13 and EGFR expression (Fig. 3.6). 
EGFR inhibitors such as gefitinib, erlotinib or lapatinib, which also inhibits ErbB2, 
have been successful in the treatment of HCC in animal models and in other human tumours 
such as non-small cell lung carcinoma. Surprisingly, the use of EGFR inhibitors has shown 
only limited success in HCC patients during clinical trials [105, 106, 107].  Furthermore, it 
was shown that EGFR plays distinct roles in hepatocytes vs Kupffer cells during HCC 
development [94]. A hepatocyte specific depletion of EGFR was shown to promote tumour 
growth whereas a deletion of EGFR in the kupffer/macrophages in the liver reduced HCC  
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growth in mice [94]. Interestingly, the authors further propose that EGFR positive 
macrophages (in the tumours) and not EGFR positive HCC cells provided prognostic values 
for overall survival in patients [94].  
In light of the above findings, it might not come as a surprise that we observed 
minimal effects on HCC cell proliferation upon depletion of EGFR alone. Many other growth 
factors or their receptors are similarly deregulated in HCC and could directly or indirectly 
influence EGFR signaling. A compensatory increase in hepatic growth factor/c-MET 
signaling has been demonstrated during EGFR inhibition, possibly to compensate for the 
impaired hepatocyte proliferation [95]. It seems that simultaneous targeting of several growth 
factor pathways was necessary in here in order to exclude possibilities of functional 
redundancies amongst signals involved during hepatocyte regeneration and carcinogenesis. In 
order to further verify the relevancy of EGFR signaling in our context, it would be notable to 
molecularly dissect and characterize the various HCC cell lines (the different oncogene gene 
mutations, EMT status etc.) before deciding on the appropriate combinations of receptor 
tyrosine kinases (RTK) inhibiting-strategies to study during hepatocarcinogenesis.  
As we do not have evidence to prove a direct interaction or promoter binding between 
TRIP13 and EGFR, the decrease in EGFR levels upon TRIP13 depletion could well have 
been secondary effects on gene expression upon DNA damage checkpoint inductions. It has 
been well described that changes in global gene expression in response to checkpoint 
inductions may derive either directly from gene transcriptional regulation or indirectly due to 
effects secondary from cell synchronization (resulting from growth arrest) [111-113]. In this 
case, it would be important to distinguish whether TRIP13 indeed exerts a direct effect on 
EGFR levels or these are simply unspecific changes secondary to growth arrest.         
 
 
4.5 The role of TRIP13 in DNA damage repair pathway and the 
implications in liver diseases and tumourigenesis 
 
 
 4.5.1 YAP as a regulator of TRIP13 in CIN signatures 
 
Chromosomal instability (CIN) represents a persistent hallmark of human solid 
tumours [37, 38]. Genetic alterations and genomic instability have long been recognised as a 
common feature between human chronic liver disease (CLD) and liver cancer [41, 66]. It was 
not until recently in 2017 that the molecular mechanisms linking this progression from 
increased hepatocyte regeneration (in CLD) to eventual liver tumourigenesis has been 
revealed [20, 39]. The authors proposed that Caspase 8 mechanistically links the increase of 
hepatocyte apoptosis during compensatory proliferation in CLD to later HCC development 
[20]. In the second study, the authors reported that a collective gene signature, termed the 
CIN25, stratified HCC patients with poor survival and early cancer recurrence [39]. The YAP 
protein, which forms part of the Hippo signalling pathway was found to be essential in 
regulating the expression of this CIN25 signature in HCC.   
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As introduced in section 2.2, TRIP13 was identified as one of the top 25 ranked CIN 
signature genes (CIN25) along with FOXM1 and MAD2L1, which were induced by an 
overexpression of YAP in liver tumour cells [39]. Indeed, we have seen a corresponding 
decrease in TRIP13 and EGFR levels upon YAP depletion in HCC cells (Fig. 3.18) It is 
feasible that the YAP/FOXM1 is regulating downstream target genes including TRIP13 in 
accounting for chromosomal instability seen in HCC patients displaying CIN25 signatures 
[39].  
 
4.5.2 TRIP13 in DNA damage and repair pathway 
 
In SCCHN, high expression of TRIP13 was shown to be the main mechanism through 
which chemoresistance develops as these tumour cells have an enhanced ability to repair 
DNA damages acquired during the genotoxic assaults [45].  
Our observations are in line with what has been reported of TRIP13 as a regulator 
during DNA damage repair [45, 88]. Firstly, we noted a remarkable upregulation and an 
essential role of Trip13 during hepatocyte regeneration post PH. Secondly; TRIP13 depletion 
resulted in severe proliferation defect and DNA damage in HCC cells. The plausible 
relevance of Trip13 under this chronic cycle of inflammation-necrosis-regeneration was 
further demonstrated by its upregulation in mouse and human CLD and across all etiologies 
of human HCC from our data. What these previous papers [45, 88] did not address however 
was the oncogenic pro-proliferative aspect that TRIP13 exerts. Besides indirectly 
recapitulating the regulatory role of TRIP13 during DNA repair in CLD and HCC, we have 
observations that suggest a DNA repair-independent role of TRIP13 during cell proliferation. 
A decrease in c-MYC along with growth promoting factors like EGFR and Cyclin D1 
suggest that TRIP13 could be directly or indirectly involved in signalling pathways that 
determine cell proliferation. Furthermore, there was no rescue of proliferation defect in 
TRIP13-depleted cells when the major DNA damage response (DDR) and DNA repair 
pathway mediated by ATM was blocked in Fig. 3.19D. In the same direction, a remarkable 
reversal of proliferation defect in TRIP13-depleted cells upon concomitantly depleting 
SIN3A was observed, albeit the persistence in high levels of DNA damage markers of p-
γH2AX and cleaved-PARP (lower level than TRIP13KD alone).  
On a separate note as mentioned in section 4.4, we discussed the possibility of 
changes in gene expression, which could be mediated directly via transcriptional regulation 
or indirectly due to checkpoint activation in response to DNA damages [111-113]. 
Performing global transcriptome profiling on HCC cells arrested in different cell cycle phases 
would be necessary to distinguish whether the changes in gene expression of c-Myc, EGFR, 
etc. that has been observed upon TRIP13 depletion are indeed specific effects or secondary 
effects to growth arrest in specific cell cycle phase (for instance in G2).     
Nonetheless, our current findings suggest that the increase in DNA damage during 
TRIP13 depletion alone was not sufficient to explain the severe proliferation impairment in 
HCC cells. It is likely that a continuous activation of signalling cascades associating with cell  
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proliferation and survival is pivotal during tumourigenesis, where the reversal of malignant 
phenotypes occurs when these central pathways are targeted.  
In this scenario, we imagine a possible cross talk between c-MYC, p53 and TRIP13. 
A high expression of TRIP13 and c-MYC commonly observed in human cancer increases 
cell proliferation by accelerating mitotic progression, leading to increased frequencies of 
mutations, replication errors and subsequent genomic instability in these cells [114]. Most 
cells entering cell cycle with DNA damage are expected to die due to arrest responses 
orchestrated by p53.  Interestingly, TRIP13 was shown as an antagonist against p53-induced 
cell death activities during the recovery phase of damaged renal epithelial cells [88]. 
Upregulated expressions of c-MYC coupled with inactivation of p53 are indicators for poor 
prognosis and early cancer recurrence in HCC patients [74,101]. In this instance, a random 
mutational inactivation of p53 or an antagonist against p53 (for instance TRIP13) might just 
create a highly tolerable environment whereby cells overexpressing c-MYC and TRIP13 can 
both drive mitotic progression and cell proliferation in spite of gross chromosomal 
abnormalities. 
 
 
4.6 Concluding remarks and outlook 
A role of TRIP13 during liver regeneration and liver cancer has not been previously 
descripted and would serve as an interesting basis to further understand the link btw CLD and 
subsequent HCC development. This brings us to the next question as to why an upregulation 
of TRIP13 during CLD and HCC seems essential under this hyper-proliferative state. From a 
functional point of view, the induced expression of TRIP13 might be a compensatory 
mechanism acquired by the cells in an attempt to maintain genomic stability by repairing 
DNA damages from an aftermath of rapid proliferation. As shown in head and neck cancer, 
TRIP13 preferentially adopts a non-homologous end-joining (NHEJ) pathway during DNA 
repair, which is a form of repair requiring less DNA fidelity (no DNA template required) and 
results in frequent DNA mismatches [45]. Together with the proliferation-promoting 
oncogenic role of TRIP13, which has been illustrated throughout our findings, these two 
TRIP13-dependent roles could set the fertile ground for eventual cellular transformation to 
occur in hepatocarcinogenesis and other cancers. 
The interesting observation from SIN3A, identified as a TRIP13-interaction partner, 
when concomitantly depleted reverses the proliferation defect in TRIP13-depleted cells is 
exciting as it reveals a potential aspect of regulation between HDAC co-factors and 
oncogenes. These finding needs to be further validated in in vivo settings during HCC 
tumourigenesis in order to accurately reflect the functional relevance of an interaction 
between TRIP13 and SIN3A. It would be interesting to observe whether these proliferation 
rescued cells (TRIP13+SIN3A depleted) are still able to sustain cell proliferation in spite of 
an accumulation of massive DNA damage or whether these DNA damages could be 
eventually resolved over time. 
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To further probe for a novel cross talk between TRIP13 and c-MYC, it would be 
critical to first determine whether this cross talk occurs on a transcriptional level or post-
transcriptionally. A dual luciferase reporter assay couple with ChIP and protein stability/half 
life test would be one of the few ways to test this out. Once this mechanistic interaction has 
been figured out, it would be noteworthy to bring this further onto in vivo studies. A plethora 
of studies have been conducted using various transgenic mice models overexpressing c-MYC 
to study HCC. A mice model with an inducible-overexpression of c-MYC specifically in 
hepatocytes [108, 109] would be extremely valuable to enable us to test this hypothesis of a 
signalling/interaction axis of TRIP13-c-MYC-SIN3A. In an orthotropic HCC implantation 
study, the ability of c-MYC overexpression to reverse the proliferation impairment of 
TRIP13-depleted HCC cells could be examined both spatially and temporally.   
Given that TRIP13 forms part of the CIN25 signature during HCC, it would serve as a 
good biomarker during early screening of patients especially those from a high-risk group 
(with cirrhosis or present with a history of CLD background) as a preventive measure against 
HCC.  
Furthermore, the expression of TRIP13 along with a predefined set of biomarkers for 
instance the CIN25 signatures, c-MYC; p-53, etc. might serve to better stratify patients for 
treatment options and prognostic outcomes. c-MYC currently represents an undruggable 
target as transcription factors do not harbour enzymatic activities or domains that could be 
pharmacologically targeted with small molecule inhibitors. TRIP13 might represent an 
alternative druggable target in here to disrupt cross talks with c-MYC or to deplete c-MYC 
levels, resulting in loss of function of relevant downstream target genes. A potent and 
selective small molecule inhibitor against p97, a member of the AAA
+
-ATPase family has 
been recently demonstrated to display antitumour activities across a broad range of solid 
tumour models [110]. TRIP13, being a member of the same family could similarly represent 
a novel and unique druggable target for HCC and other cancer entities.   
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5 Material and Methods 
 
5.1 Methods 
 
5.1.1 Cell culture 
 
5.1.2 Cell lines  
Human hepatocellular carcinoma (HCC) cell lines of HLF, Huh7, HepG2 and Mouse HCC 
cell lines of Hepa1-6 were used. A non-transformed Mouse liver cell line of AML12 was 
used to test for oncogenic properties of Trip13. The cell line identities have been separately 
verified to ensure that no cross contaminations between different cell lines have occurred. 
HLF cells were a kind gift from Dr. Iryna Ikavets; Huh7, HepG2 and AML12 were 
obtained from ATCC. 
 
5.1.2 Cultivation of cells  
All cells were cultured in 10 cm-plates in 10 ml of high-glucose DMEM supplemented with 
10% heat-inactivated FBS and 1% of penicillin/streptomycin all from Gibco in a humidified 
incubator at 37°C with 5% CO2. For normal cell line maintenance, fresh media was given to 
cells 2 times per week and cells were subcultured once per week when cell confluency 
reaches between 80%-90%.  
For subculturing, cells were first washed with 5 ml of DPBS (Gibco) to remove residual 
culture media and serum before being detached from the cell culture plate using 1 ml of 
0,05% Trypsin (Gibco) between 3-5 mins incubation in the 37°C incubator. The 
trypsinization step was stop by resuspending cells in 10 ml of full DMEM media + FBS. The 
resuspended cells were centrifuged for 3 mins at 500 x g, resuspended in 10 ml of fresh 
culture media and 1 ml of this cell suspension was reseeded into a 10 cm dish. Cell 
morphology was assessed in an inverted light microscope (Olympus).   
To seed cells into different cell culture dish formats for experiments, 10 μl of cell suspension 
was taken from the last step of the cell resuspension and mixed with 10 μl of trypan blue 
solution. Cells were then counted manually using either a Neubauer cell counting chamber or 
using the Countess
TM 
automated cell counter. The cell concentrations were determined and 
the appropriate numbers of cells were seeded according to the surface area of the dishes and 
the purpose of the experiments.  
 
5.1.3 Freezing and thawing of cells  
Cells were trypsinized as described in the section above. After cells were counted and cell 
concentrations were determined, cell densities were adjusted to 2x10
6
 cells /ml by dilution 
with an appropriate volume of cell media. Thereafter, a freezing media mixture consisting of 
a final concentration of 40% FBS, 10% DMSO and 50% full DMEM media containing 1x10
6
 
cells were aliquot in a volume of 1 ml into cryogenic vials. These vials were then put into a 
Mr Frosty
TM
 freezing container (ThermoFischer Scientific) overnight in -80°C to allow cells 
to gradually cool down to freezing temperatures.  
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The following day, one cryovial of cells were taken out from -80°C to be thawed to test for 
cell viability after freezing before this batch of frozen cells are transferred to the liquid 
nitrogen tanks. During this cell thawing process, one frozen cryovial is thawed in the 37°C 
water bath for 1-2 minutes before being transferred into a falcon tube containing 9 ml of full 
DMEM media. The cell suspension is centrifuged for 3 mins at 500 xg to remove the DMSO 
freezing media before being resuspended in 10 ml of full DMEM media for plating in a 10 
cm dish.  
 
5.1.4 siRNA and plasmid transfections 
An overview of all the plasmids and Target-on pooled siRNA oligos (Dharmfect) used 
throughout the thesis is outlined in the material section. One day prior to cell transfection at 
D0, cells were trypsinized and seeded into either 6-well or 12-well plates as described in 
5.1.2. Cells were resuspended and plated in antibiotic-free full DMEM media to reach a 
confluence of 60-70% the next day for transfection.  
Target-ON plus siRNAs (Dharmafect) ordered in the format of lysophilized salt are 
reconstituted using 1x siRNA buffer (Dharmafect) into a stock concentration of 50μM. The 
siRNA oligo tubes were spin briefly before being resuspended in an appropriate volume of 
buffer, placed on a shaker at 300rpm for 30 mins at RT before being aliquoted into 10 μl 
volumes for long term storage in -20°C or -80°C.   
siRNAs were then further diluted in 1x siRNA buffers into working stocks of 5μM before 
being used at a final concentration of 25nM during transfections. During double siRNA 
transfections, the final amount of siRNAs used was titrated with the NTC siRNA to ensure 
that all groups received an equal amount of siRNAs. The set up of a transfection reagent mix 
using siRNAs is shown for a 12-well culture dish in table 1 , which was similarly applied to a 
6-well culture dish by multiplying every volume by a ratio of 2. Components in tube A and B 
were assembled separately and incubated for 5 mins at RT. The two tubes were then 
combined and incubated at RT for 20 mins before being added drop wise to the culture 
media. For every transfection set up, one well of cells would be transfected with a NTC 
siRNA that has been coupled with a GFP tag to assess for RNAi transfection efficiency in 
this particular experiment. After an incubation of at least 7 hours at 37°C, the transfection 
reagent was removed from the cells and replaced with fresh antibiotic-free full DMEM media 
for overnight incubation. Cells were either trypsinized the next day and reseeded in 96-well 
plates for cell-based assays or further cultured for 72 hours for RNA and protein extractions 
Transfections with plasmids were performed following the same set up as shown in the below 
table, except where plasmids are used in a final amount of 500ng and lipofectamine 2000 
(Invitrogen) was used instead of RNAi max (Invitrogen) reagent. As a control for DNA 
transfection efficiency, one well of cells was transfected with an enhanced-GFP empty 
plasmid vector.      
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  Table 1: Set up of siRNA transfection regents for cells seeded in a 12 –well dish 
 
 
 
5.2 Cell-based assays 
 
5.2.1 Cell counting kit-8 (CCK8) 
Cell numbers and cell viability was assessed using a CCK8 reagent from Sigma-Aldrich. This 
is a highly sensitive enzyme-based colorimetric assay, which makes use of water–soluble 
tetrazonium salts called WST-8 to assesses cell viability during proliferation and cytotoxicity 
assays. WST-8 is bioreduced into an orange-coloured formazan dye by cellular 
dehydrogenases; therefore the amount of formazan produced is directly proportional to the 
number of viable cells.  
During the initial optimization of assay conditions for using the CCK8, a serial cell dilution 
process was performed and it was determined that 5000 cells/well during seeding was the 
optimum cell seeding number for all HCC cell lines over a course of 4 days of growth assay. 
Due to the slower growth rate of AML12 cells, 8000 cells to be seeded per well was 
necessary in order to achieve a good correlation between absorption readings and viable cell 
numbers. One day after transfection, cells were trypsinized and 5000 cells in 100 μl 
volumes/well were seeded into 96-wells for different cell-based assays. At least 4 repeats 
were seeded per experimental conditions and cells were pre-incubated overnight to regain cell 
viability prior to the CCK8 assay the next day. 10 μl of CCK8 was added to each 96-well 
(cells incubated in 100 μl of cell media) and incubated for colour development at 37°C with 
5% CO2. HLF, Huh7 and Hepa1-6 cells were incubated for 2.5 hours whilst AML12 and 
HepG2 were incubated for 3 hours for colour development before the readings for absorbance 
were taken at 450nm. 
Due to the low cytotoxicity of the CCK8 reagent, the same cell wells can be used repeatedly 
for cell proliferation measurements over the entire course of the experiment. The existing 
CCK8 reagents are removed from the wells, washed once in 1x PBS before 100 μl of fresh 
cell media is added to each well for repeated cell number measurements over the next days.   
 
5.2.2 BrdU cell proliferation assay 
Cell proliferation was measured using the BrdU cell proliferation ELISA kit from cell 
signalling. This assay kit detects the amount of the base analog, 5-bromo-2’deoxyuridine 
(BrdU) that is being incorporated into the cellular DNA during cell proliferation by using an 
anti-BrdU antibody, therefore providing a direct indication of cell proliferation.  
 Tube A Tube B 
Reagents siRNA (5 μM) Opti-MEM RNAi max reagent  Opti-MEM 
1 x 5 μl 95 μl 4 μl 96 μl 
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At D3 post transfection, the BrdU labelling reagent from the kit is added at a dilution of 
1:1000 (10 μM) to cells previously seeded in 96-well plates and cells are returned to the 
incubator for 4 hours at 37°C with 5% CO2. After removing the BrdU labelling medium, the 
cells are fixed and DNA denatured at 30 mins RT using 100 μl/well of the fixing/denaturing 
solution as provided. The Mouse BrdU detection antibody is then diluted 1:100 in the 
antibody diluent provided and 100 μl/well is added and incubated for 1 hr at RT. The cells 
were then washed 3 times with 1x of wash buffer as provided before being incubated for 30 
mins at RT with the anti-Mouse HRP conjugated Mouse antibody (diluted 1:100 in antibody 
diluent). Finally, cells were washed for 3 times with 1x wash buffer and 100 μl/well of HRP 
substrate TMB is then added for colour development for 30mins at RT in the dark. The 
colour development is stop by adding 100 μl/well of STOP solution. The absorbance is read 
at 450 nm where the magnitude of the absorbance provides a direct indication of cell 
proliferation in each well.  
 
5.2.3 Apoptosis detection assay  
The Apo-ONE
®
 Homogeneous Caspase-3/7 Assay from Promega was used to measure the 
amount of active caspase-3/7 present in cells being subjected to different experimental 
treatments. This assay includes a profluorescent caspase-3/7 consensus substrate, Z-DEVD-
R110, which upon cleavage of the C-terminal Aspartate residue of this peptide sequence by 
caspase-3/7 produces a fluorescent product that is indicative of the active caspase levels in 
the sample. 
The Apo-ONE
®
 Caspase-3/7 reagent was prepared by diluting the provided substrate 1:100 
with the buffer to obtain a volume of 50 μl/well in a 96-well plate. To obtain a 1:1 ratio of 
substrate reagent to sample volume, 50 μl of the culture medium was removed from each 96-
well cell culture sample. 50 μl of the prepared Caspase-3/7 reagent was then added to each 
well containing 50 μl of cells in culture and cells were lysed and homogenized on a shaker at 
400 rpm for 15 mins. The samples were then further incubated for 4 hrs at RT in the dark to 
allow for the Caspase 3/7-enzymatic reaction to proceed. Once the incubation period was 
over, the Caspase 3/7 activities from each well were measured at a fluorescence excitation 
wavelength of 495nm and emission wavelength of 525nm. The results from the assays were 
plotted as relative fluorescence units (RFU) to indicate the activity levels of caspase3/7 in 
that sample condition.   
  
5.2.4 Immunohistochemistry (IHC) fluorescence staining  
Intracellular localization of different protein targets was verified using the IHC fluorescence 
staining protocol as outlined below. HLF, Huh7 and HepG2 cells were first trypsinized and 
seeded at a density of 2x10
4
 cells/well in a 8-chamber Labtech Microscopy Slide and 
incubated overnight at 37°C with 5% CO2. The following day, cell medium was removed 
and cells were washed once with cold PBS before being fixed with 4% formaldehye/PBS for 
10 mins at RT. Cells were then permeabilized with 4%formaldehyde/0,1% Triton-X in PBS 
for 5 mins on ice. Thereafter, cells were washed 4 times for 2 mins each in PBS before being 
blocked in 5%BSA/10%FBS/PBS for 1 hr, shaking at RT.  After the blocking step, primary  
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antibodies that have been diluted in blocking solution are added to cells and incubated in a 
humidity chamber overnight at 4°C. 200 μl/well of reagents were used for every step except 
when 100 μl/well was used during the primary antibody incubation step. The next day, the 
primary antibodies were removed and cells were washed 3 times with PBS for 5 mins each. 
The corresponding secondary antibodies coupled with either Alexa-Fluor
®
 488 or 555 were 
added to cells for 1 hr at RT protected from light. Finally, cells were washed thrice for 5 mins 
with PBS before being mounted in DAPI-VectaSheid with microscope coverslip and the 
edges of the slides are then sealed with nail vanish. Microscopic slides were store at 4°C in 
the dark before being imaged using the Olympus confocal microscope FV1000 under the 
GFP, FITC and DAPI channel. Cells were imaged at a thickness of 5 μM either with a 20x air 
or a 40x oil-immersion objective. Using the Olympus fluoview software, the maximum 
projection Z-stacks were merged thereafter for image analyse. 
 
5.2.5 In situ Proximity ligation assay (PLA)  
DuolinkTM in situ reagents from Sigma Aldrich was used in order to perform the in situ PLA 
to verify for intracellular interactions between TRIP13 and its MS-identified interaction 
targets of SIN3A and SAP130 in fixed HCC cell culture samples. The interaction between 2 
proteins is detected using 2 corresponding antibodies raised in different species. Species-
specific secondary antibodies (species-specific PLA probes that are conjugated with a unique 
short sequence of DNA) then bind to the primary antibodies. When the two (plus and minus) 
PLA probes are in close proximity (< 40nm), these DNA strands can interact through a 
subsequent addition of 2 circle-forming DNA oligonucleotides. A fluorescent signal is then 
generated during the incorporation of fluorophore-labelled complementary oligonucleotide 
probes during further amplifications of the DNA circle. Therefore each fluorescent spot 
represents a single interaction that can be quantified and assigned to a specific cellular 
localization during confocal imaging.  
A brief outline of the PLA protocol optimized for HLF/HUH7 is as follows: 
1. Seeding and processing of cells in chamber slides                                               
The process from seeding of cells into chamber slides (8-well) overnight; fixing, 
permeabilizing and blocking for 1 hr at RT are exactly as what was performed during 
immunofluorescence staining in section 5.2.4.  
2. Adding Primary antibodies for use in PLA                                                         
These antibodies for use in PLA must be raised in different species. For this reason the 
following combinations of antibodies were used: TRIP13 (Rabbit)+SIN3A (goat); 
TRIP13(R)+SAP130 (G) and SIN3A(R)+SAP130 (G) to detect for interactions between 
these proteins under investigations. lgG from the same isotypes and antibodies from the 
same species were used for negative controls. TRIP13 was diluted 1:100, Sin3A 1:50 and 
SAP130 1:100 in blocking solution. 50 μl of antibodies diluted in blocking solution was 
added to each of these chamber wells and the wells were sealed with a parafilm before 
being incubated overnight at 4°C in a humidity chamber. 
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3. Adding PLA plus and minus probes       
All washes are done at RT with gentle shaking unless otherwise specified. The next day, 
the primary antibodies were removed and cells were washed for 3 x 5 mins in PBS. 
Rabbit PLA plus and Goat PLA minus probes are used in here. The two PLA probes are 
diluted 1:500 in the PLA diluent as provided, added at a volume of 50 μl per well and 
incubated for 1 hr at 37°C in a humidity chamber. 
4. The chamber gaskets that are separating the wells from each other in the chamber slides 
can now be removed. A PAP pen is used to mark around each cell-well area and all 
subsequent washes are done in Coplin jars. Slides are then washed 2 x 5 mins in PBS to 
remove the residual PLA probes.  
5. Ligation step (For ligase to add DNA nucleotides to the two PLA probes that will join 
into a circle if these pairs are in close proximity) 
The ligation stock is diluted 1:5 in water to make the ligation solution. Ligase provided is 
diluted 1:40 in this solution and added at 40 μl/well and incubated for 30 mins at 37°C 
for the ligation process to take place. 
6. Rolling circle DNA amplification                               
The ligation mix is removed and slides were washed 2 x 5 mins in PBS. The 
amplification stock was diluted 1:5 in water and DNA polymerase was diluted 1:80 in 
this solution. 40 μl /well of this amplification mix was added and incubated for 100 mins 
at 37°C.   
7. Final washing and mounting of slides 
The amplification mix was tapped off and slides were washed 2 x 5 mins again in PBS 
before being air dried in the dark for 2-3 mins. Slides were mounted with a coverslip 
using DAPI vectashield and stored at -20°C until imaging. 
8. Detection of red fluorescent amplification signals 
Confocal imaging to detect for amplification signals were performed using at least 20x 
magnification objective and using the FITC filter. DNA were stained with DAPI and 
imaged under the ultraviolet excitation/emission filter.  
 
5.2.6 Dual luminescence assay 
 
The GLuc-ON
TM
 human EGFR promoter reporter construct (EGFR-HRP pEZX-G04) from 
Genecopoeia was used in experiments to detect for changes in EGFR promoter activities. 
This dual reporter system uses the secreted Gaussia luciferase (GLuc) as the promoter 
reporter and the secreted alkaline phosphatase (SEAP) as an internal control to enable 
transfection normalization across samples. GLuc and SEAP are both secreted into the cell 
media and can be detected by the secrete-pair
TM
 dual luminescence assay kit without cell 
lysis. This EGFR HRP dual-reporter vector is co-transfected with siRNAs in HCC cells using 
lipofectamine 2000 following transfection protocols in section 5.1.2. Cell culture media were 
collected at 48 hrs and 72 hrs after transfection and stored in -20°C before samples were 
analysed. A 1x assay working solution was constituted with the GLuc substrate, 
coelenterazine, as provided. The assay was set up in a 96-well all-round white opaque plate. 4 
repeats (10 μl) was pipetted from each experimental condition and 100 μl of the 1x working 
assay solution was added and luminescence reading was taken within the first 5 mins of the  
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reaction with the bioluminescent filter of the plate reader. The results are subsequent plotted 
as relative light units (RLU). 
 
 
5.3 Virus work 
 
5.3.1 Lentivirus shRNA vector constructs 
A set of Lentiviral pLKO.1 vectors containing 4 unique 29-mer shRNA constructs against 
human SIN3A was purchased from Origene in the form of dried plasmids (TL301698). The 
scrambled negative control (TR30021) shRNA cassette in the same pLKO.1 plasmid 
backbone was obtained from Origene. These dried plasmids were subsequently reconstituted 
with H2O into a final concentration of 100 μg/μl and transformed into DH5α bacterial cells 
for plasmid amplification. Lentiviral packaging vectors of psPAX2 (Cat. No. 12259) and 
pMDG.2 (Cat. No. 12260) were available in the lab plasmid database that were originally 
obtained from Addgene with the catalogue numbers as stated.     
 
5.3.2 shRNA transfections to pre-select constructs with a good Knockdown 
HEK293T cells were seeded into 6-well plates at 2,5x10
6
 cells/well. The next day, 
transfections with the four different SIN3A specific shRNA constructs were performed using 
lipofectamine 2000 following the transfection protocol in section 5.1.4. At D3-post 
transfection, protein lysates were harvested from cells and immunoblotted to select 2 of the 
shRNA constructs that gave the best SIN3A knockdown. These shRNA plasmid constructs 
were used for subsequent lentivirus production. Prior to lentivirus production, these 2 
selected shRNA constructs were subcloned into another pLKO.1 plasmid vector backbone 
containing Blasticidin resistance also from Origene (TL30032), details are in the molecular 
cloning in section 5.7.    
 
5.3.3 Lentivirus production 
HEK293T cells were seeded into 10 cm plate at an amount of 3.8 x 10
6
 cells/plate. The 
following day, the selected PLKO.1 vectors and packaging plasmids were transfected into 
cells in the following way: 
9 μg of pLKO.1 vector, 9 μg of psPAX2 and 0,9 μg of pMD2.g were diluted into 800 μl of 
Opti-Mem in a 1,5 ml tube for each 10 cm plate. In the second tube, 15 μl of lipofectamine 
2000 was diluted into 800 μl of Opti-Mem. These 2 tubes were separately incubated for 5 
mins at RT before being mixed and further incubated for 25 mins. The plasmid-lipofectamine 
mixture (1600 μl) was then added dropwise to the cells. The next day, fresh media containing 
BSA was given to the cells (Full DMEM+ 10% FBS+ 1.1% BSA) and further incubated at 
37°C in the incubator. 48 hrs after transfection, the cell media (containing packaged viruses) 
was harvested. Media was first centrifuged at 1250 rpm for 5 mins and passed through a 0,45 
uM filter fitted syringe to remove cell debris before being stored at -80°C. Fresh media 
containing BSA was again given to cells to repeat for media harvesting the following day  
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following the exact protocol. Virus supernatant from 48 hrs and 72 hrs post virus packaging 
are pooled and virus titer of supernatant was determined via qPCR to quantify for expression 
of HIV p24 antigen. 
 
5.3.4 Lentivirus titer calculations 
ABM's Lentiviral qPCR Titer Kit (LV900) was used to determine the virus titer from cell 
supernatant collected from above.  2 μl of the cell supernatant was lysed with 18 μl of the 
virus lysis buffer as provided and incubated for 3 mins at RT. The Ct value of this viral lysate 
is used for subsequent calculations to determine the viral titer of the supernatant. A single 
step RT-qPCR reactions are set up in triplicates as follow: 12,5 μl of 2X SYBR green qPCR 
mastermix and 10 μl of reagent-mix are added to 2,5 μl of viral lysate. The qPCR reactions 
for the lentivirus standard 1 (STD1) and lentivirus standard 2 (STD2) are set up in the same 
way by adding 2,5 μl of STD1 or STD2 instead of the viral lysate. The reagent mix provided 
by the kit already contains primers and reagents for reverse transcription of the RNA 
template. The RT-qPCR program is set up like a usual PCR program with the exception of an 
additional RT step at the start. The reactions were ran in the (Thermo Fisher) QuantStudio 6 
Flex Real time PCR system using this program: reverse transcription for 20 mins at 42°C; 
enzyme inactivation for 10 mins at 95°C; 30 cycles of template denaturation for 15s at 95°C 
and primer annealing/extension step for 1 min at 60°C. The virus titer (IU/ml) was calculated 
using this formula:  
Titer of viral lysate = 5 x 10
7
/2
3(Ctx-Ct1)/(Ct2-Ct1)
 
Ctx = Average of 3 Ct values of the unknown viral lysate 
Ct1 = Average of 3 Ct values of STD1 
Ct2 = Average of 3 Ct values of STD2 
 
 
5.3.5 Lentivirus transduction and establishing stable cell lines 
HLF cells were seeded at 2 x 10
5
 cells/well in a 6-well plate with antibiotics-free full DMEM 
media. The next day, 1 ml of fresh antibiotic free media with 8 μg/ml of polybrene was given 
to each well. 1 ml of opti-MEM with 8 μg/ml polybrene plus lentivirus was added at an MOI 
of 5 -20. The next day, cells were given fresh anitbiotics-free media and further incubated. 
After 3-4 days post virus transduction, cells are trypsinized and subcultured into 6 well plates 
for antibiotic selection with blasticidin (2 μg/ml). Cells were further expanded in 10 cm 
plates under constant antibiotic selection process over 2 weeks. In the meantime, a small 
amount of cell lysates are harvested and tested for protein knockdown of SIN3A before the 
cell line is considered to be a stable cell line for SIN3A KD. These stable cells lines 
containing either the control shRNA construct or the SIN3A-targeted shRNA construct are 
frozen and kept subsequently in the liquid N2 tank for long-term storage.  
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5.5 RNA methods 
 
5.5.1 RNA extraction from cell culture samples  
Cells were washed once with cold PBS before being lysed directly on the wells for RNA 
extraction following the typical TRIzol (Sigma) phenol-chloroform extraction method. RNA 
was precipitated from the extracted aqueous organic phase by adding 700 μl of isopropanol to 
every 1 ml of TRIzol added, vortexed vigorously and centrifuged at 13 000 rpm for 30 mins 
at 4°C. The RNA pellet was washed once with 75% ethanol before being air-dried on the heat 
block at 55°C for 5 mins until all residual ethanol has evaporated. The RNA pellet was 
reconstituted into 50 μl of RNase free H2O and placed onto the heat block again at 55°C for 
10 mins. The final RNA concentration, 260/280 and 260/230 ratios were determined using 
the NanoDrop spectrophotometry. RNA was then stored in -20°C for short term and -80°C 
for long-term storage. 
 
5.5.2 Reverse transcription of RNA to form cDNA  
QuantiTect Reverse Transcription kit form Qiagen was used for synthesizing cDNA 
(complementary DNA) from RNA extracted. 1 μg of RNA was diluted into 12 μl of nuclease 
free water. Genomic DNA (gDNA) was first removed by adding 2 μl of gDNA wipe out 
buffer and incubating for 2 mins at 42°C on the Thermo Heat block and back on ice. The 
reaction mix is set up by adding 4 μl of QuantiTect reverse transcriptase (RT) buffer, 1 μl of 
RT primer and 1 μl of RT to each RNA sample. The reverse transcription reaction is 
incubated for 30 mins at 42°C before the reaction was stop by increasing the temperature to 
95°C for 2 mins. 80 μl of nuclease free water are added to the resulting cDNA solutions and 
these diluted cDNA (equivalent to 10 ng/μl of initial RNA) are used for later qPCR reactions. 
 
5.5.3 TaqMan qPCR to quantify for gene expression   
qPCR reactions were set up in 10 μl per well in MicroAmp optical 384-well reaction plates 
with triplicates /sample as follow:  
qPCR set up using TaqMan ®probes  Volume per sample  (ul) 
10 ng/μl cDNA 2,5 
TaqMan probe 0,25 
TaqMan ® Gene expression Master Mix 5 
Nuclease free water  2,25 
 
The plate was sealed with MicroAmp optical Adhesive film; briefly centrifuged for 2 mins at 
2000 rpm and amplification was performed in the Thermo Fischer Quantstudio 6 Flex 
instrument, 384-well block. The temperature profile for the PCR cycle used was: 2 mins at 
50°C, 10 mins at 95°C then 40 cycles of 15 secs at 95°C followed by 1 mins at 60°C. The  
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ΔCT values are obtained by subtracting the CT value for gene of interest from CT value of the 
housekeeping gene TBP of the same sample. This ΔCT is then converted to relative gene 
expression to TBP using this formula for relative expression:  2
- Δ
 
CT
. 
 
 
5.6 Protein methods 
 
5.6.1 Protein extraction from cell culture 
Cells were washed once in cold PBS on ice before being lysed in RIPA buffer supplemented 
with protease and phosphatase inhibitors (Sigma). All steps were performed on ice or at 4°C 
unless specified. To a 6-well plate, 400 μl of RIPA buffer was added per well and cells were 
lysed for 30 mins on ice. Thereafter, the cell lysates were collected and transferred into 1,5 
ml tubes. Depending on the viscosity of the cell lysates, sonications were also performed 
using the Bioruptor Plus Sonicator for 3 cycles of 10 secs at low intensity for viscous lysates. 
20 μl of the cell lysates are put aside for subsequent determination of protein concentration 
whilst the rest of the lysates are stored at -20°C or  -80°C until further use. 
 
5.6.2 Determination of protein concentrations  
Protein concentrations were determined using the Pierce BCA assay kit on 96-well microtiter 
plates. BSA standards in a range of 0,025– 2 mg/ml were prepared beforehand by serial 
dilution of the BSA stock (2 mg/ml) in water. 10 μl of the protein sample or of the BSA 
standards were pipetted in duplicates with 200 μl of assay reagent per well. BCA assay was 
incubated for 30 mins at 37°C for purple coloration to develop and absorbance values were 
measured in the plate reader at 560 nm. Protein concentration of samples was extrapolated 
and calculated from BSA standard curve generated during the assay.     
 
5.6.3 SDS-polyacrylamide gel electrophoresis   
20-40 μg of proteins were diluted in H2O and 5x SDS loading dye to a final volume of 40 μl, 
then denatured for 7 mins at 95°C, shaking on the heat block. Samples are cooled briefly on 
ice before being loaded onto 8-12% gradient SDS- polyacrylamide gels that has been placed 
into gel chambers filled with 1x SDS running buffer. Electrophoresis was performed at 90-
120 V for 1,5- 2 hrs with powerpac from Biorad. 5 μl of Precision Dual stain protein ladders 
from Biorad was used as a size standard.    
 
5.6.4 Protein transfer and immunoblotting  
Protein transfer was performed using a wet blot system. After gel separation, gels were 
removed from the gel cassettes and submerged briefly in the SDS transfer buffer. A sandwich 
array was assembled in the transfer cassette in the following order: a sponge pad, 1 gel-sized 
Whatman filterpaper, 1 gel-sized 0,45 μM nitrocellulose membrane, gel, whatman filterpaper 
and sponge pad (all components previously soaked in transfer buffer).  Protein transfer was 
performed in Tris-glycine-SDS transfer buffer for 1,5 hrs at 90 v at 4°C using a Mini trans- 
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blot cell. After the transfer, the membrane was removed and stained briefly in Poncea-S 
solution to access the quality of transfer. Staining was removed by a few washes under 
running water until no stain remained.  Membranes were blocked for 1 hr in 5% milk/TBS-T 
(0.1% Tween) before being incubated with primary antibodies overnight at 4°C. The next 
day, blots were washed for 3 x 5 mins in TBS-T before being incubated with HRP-conjugated 
secondary antibodies (refer to antibodies section) for 1 hr at RT. Blots were washed for 3 x 5 
mins in TBS-T. ECL (enhanced chemiluminescence) western blotting detection reagent mix 
was applied to the membrane, incubated for 1 min and chemiluminescence was imaged with 
the Bio-rad ChemiDoc system with Image lab software. 
 
5.7 Molecular Cloning 
 
5.7.1 Transformation of bacteria E.coli cells 
DH5α chemically competent E.coli cells were transformed by using the heat shock method. 
One aliquot of bacteria cells (50 μl) is taken out from -80°C and thawed on ice. 10ul of 
plasmid DNA in an amount ranging from 0.1 μg to 1 μg is then mixed with the cells and 
incubated for 30 mins on ice. Thereafter, cells are subjected to a heat shock at 42°C for 40 
secs in a prewarmed waterbath. These cells were given 250 μl of S.O.C medium and then 
incubated at 37°C for 1 hr on the shaker at 225 x g. Thereafter, 100 μl of these cells were 
spread onto an LB agar containing the appropriate selective antibiotics and incubated 
overnight at 37°C.    
5.7.2 Growing bacteria colonies for plasmid amplification 
The next day, single colonies are picked with a 20 μl pipette tip and inoculated into a starter 
culture containing 4 ml of LB media with the appropriate selective antibiotics. Culture was 
incubated for approximately 8 hrs at 37°C shaking at 300 x g. This starter culture is further 
inoculated into a larger culture volume of 200 ml of selective LB medium and allowed to 
grow overnight for 12-16 hrs, shaking at 300 x g at 37°C.  
5.7.3 Plasmid DNA purification 
The next day, the bacterial cells were harvested into centrifuge bottles and centrifuged at 
5000 x g for 20 mins at 4°C. All traces of the medium were removed by draining the bottles. 
The bacteria pellets were frozen in -20°C until further plasmid purification step. All 
subsequent steps were performed in accordance to the manufacturer’s protocol for the 
HispeedPlasmid Maxi kit (Qiagen). After the plasmid DNA has been finally eluted in 500 μl 
of TE buffer, the DNA yield is measured with the Nanodrop at 260nm.  Depending on the 
downstream applications, the DNA is either used for direct transfection into cells or needs to 
be further digested with appropriate RE to check for correct orientation of the inserts. In the 
latter case, the RE-digested Plasmids are then analysed by agarose gel electrophoresis.  
5.8 Nomenclature of genes and proteins  
All Mouse proteins and genes are assigned with a capitalized first letter (e.g. Trip13, Sin3a) 
whilst human proteins and genes are assigned entirely with block letters (E.g. TRIP13, 
SIN3A
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5.9 Material 
 
5.9.1  Equipments  
  
Product name Company 
Aspiration adaptor, 8-channel  Neolab  
Bacterial Incubator  ThermoFisher Scientific  
Bacterial shaking incubator  Infors HT  
Balance, Analytical, Entris, 2200g Sartorius 
Balance, Cubis, MSE623S-100DE Sartorius 
Benchtop Microfuge 20 1 Beckman Coulter 
Bioruptor® _Plus Sonicator  Diagenode  
Bunsen Burner  Campingaz  
C-4040 zoom Digital Camera Olympus 
ChemiDoc TMi XRS+ Molecular Imager®  Biorad  
Ckx41 Inverted Light Microscope  Olympus 
Comfort Thermomixer  Eppendorf 
Fluoview FV1000 Confocal microscope Olympus  
Countess II Cell counter, automated  Life Technologies 
Laminair Model 1.2 Holtern 
Magnetic Stirrer Rsm-10hs Phoenix Instruments 
Micropipette, 8-channel, 0.5-10 ml  Eppendorf 
Micropipette, 8-channel, 10-100 ml  Eppendorf 
Mini Trans-Blot Electrophoretic Transfer Cell Biorad 
Mr Frosty Freezing Container  ThermoFisher Scientific  
Multimode Microplate reader, Varioscan LUX  ThermoFisher Scientific  
Multipette® _M4 Multistep pipette  Eppendorf 
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Product  Company  
Multipette® _plus Multistep pipette Eppendorf 
Mutistep pipette  Eppendorf 
Nanodrop Nd-1000 Thermo Fischer  
Neubauer Counting chamber  Brand (Wertheim, Germany)  
Ot340 Hotplate Medite 
pH meter Qph 70 GHM Messtech  
PowerPac Basic TM gel electrophoresis Biorad 
Rotating Wheel Neolab 
TissueLyser MixerMill Retsch 
Titer plate shaker  ThermoFischer scientific 
Trans-Blot cell Biorad 
Trans-Blot, Turbo Blotting System Biorad 
Vortex Genie 2 G560E Scientific Industries, Inc 
Western Blot Tank Blotting System Mini Biorad 
 
 
5.10  Consumables  
   
Product  Company  Cat. No.  
0.1 -10 μl pipette tips Eppendorf  0030 072.006  
0.2 mL Combitips advanced®  Eppendorf  0030 089.413  
0.5 mL Combitips advanced®  Eppendorf  0030 089.421  
0.5-20 μl pipette tips  Eppendorf  0030 072.014  
1 mL syringe, Soft-Ject® _Tuberkulin  Henke Sass Wolf 5010-200V0  
1-200 μl pipette tips Eppendorf  0030 072.022  
10 mL Combitips advanced®  Eppendorf  0030 089.464  
1.5 mL safe-lock tube  Eppendorf  0030 120.086  
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Product  Company  Cat. No.  
10 cm tissue culture plate  BD Falcon™  353003 
10 mL serological pipettes  BD Falcon™  357551 
15 cm tissue culture plate  BD Falcon™  353025 
2 mL cryogenic vials  StarLab  E3110-6122  
2 mL safe-lock tube  Eppendorf  0030 120.094  
20 mL syringe  BD Falcon™  300629 
25 mL serological pipettes  BD Falcon™  357525 
5 mL Combitips advanced®  Eppendorf  0030 089.456  
5 mL safe-lock tube  Eppendorf  0030 119.460  
5 mL serological pipettes  BD Falcon™  357543 
5 mL syringe  BD Falcon™  309050 
50 mL serological pipettes  BD Falcon™  357550 
50 mL syringe  BD Falcon™  300865 
50-1000 μl pipette tips Eppendorf  0030 072.030  
Cell scraper  Corning  3010 
Corning® 96 Well Solid Polystyrene 
Microplate (White) 
Corning CLS3912 
Corning™ Falcon™ 15mL Conical 
Centrifuge Tubes 
ThermoFischer Corning, 
Inc  
 352096 
Corning™ Falcon™ 50mL Conical 
Centrifuge Tubes 
ThermoFischer Corning, 
Inc   
 352070 
Countess™ cell counting chamber slides  
Life Technologies, 
Invitrogen  
C10283  
Cover slips 24X60 mm #1  Menzel  
BBAD024006
00 
Cover slips 24X60 mm #1,5 Menzel  
BBAD024006
00 
Imaging plate, 96-well clear bottom black 
wall  
BD Falcon  353219 
Lab-Tek II CC2 Glass Chamber Slides 4-
well  
ThermoFisher Scientific 154526 
Lab-Tek II CC2 Glass Chamber Slides 8-
well  ThermoFisher Scientific 154941 
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Product  Company  Cat. No.  
Microtiter plate, 96-well  ThermoFisher Scientific  260836 
Nitrocellulose membrane, Protran® BA85, 
0.45 μm pore size 
GE Healthcare  10401196 
Parafilm® _M  Bemis®  BR701650 
PCR tube lids, flat, 8 strip  Greiner Bio-one 373250 
PCR Tubes, 8 strips, 0.2 mL  Greiner Bio-one 673210 
Petri dish for Agar plates  Greiner Bio-one 632180 
Stainless steel beads, 5 mm  Qiagen 69989 
Tissue-culture treated plate, 12-well  BD Falcon™  353043 
Tissue-culture treated plate, 24-well  BD Falcon™  353047 
Tissue-culture treated plate, 6-well  BD Falcon™  353046 
Tissue-culture treated plate, 96-well  BD Falcon™  353916 
Whatman™ paper  GE Healthcare 3030 917  
Novex™ 8-16% Tris-Glycine Mini Gels, 
WedgeWell™ format, 12-well 
Invitrogen XP08162BOX 
Novex™ 4-20% Tris-Glycine Mini Gels, 
WedgeWell™ format, 12-well 
Invitrogen XP04202BOX 
 
 
5.11  Kits 
   
 Product  Company  Cat. No.  
Apo-ONE® Homogeneous Caspase-3/7 Assay Promega G7792 
BrdU Cell proliferation kit  
Cell Signaling 
Technology  
6813S  
Cell Counting kit 8 (CCK-8) Sigma-Aldrich 96992 
Duolink detection reagentsRed Sigma-Aldrich DUO92008 
Duolink in situ PLA probe Anti-Goat Minus Sigma-Aldrich DUO92006 
Duolink in situ PLA probe Anti-Rabbit Plus Sigma-Aldrich DUO92002 
ECL Prime Western Blotting Detection Reagent Amersham 
Biosciences 
RPN2232 
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 Product  Company  Cat. No.  
Glucose (HK) assay kit  Sigma-Aldrich GAHK20-1KT  
QuantiTect Rev. Transcription Kit Qiagen 205313 
Secrete-Pair Dual Luminescence Assay Kit  Genecopoeia LF032 
Serum Triglyceride determination kit  Sigma-Aldrich TR0100  
qPCR Lentiviral titration Kit  abm Good LV900 
Lenti-X GoStix, 20 tests Takara Bio Clontech 631243 
 
 
 
  
5.12  Enzymes  
   
 Product  Company  Cat. No.  
Calf Intestinal Alkaline Phosphatase 1 U/µL Sigma-Aldrich 18009027 
FastDigest EcoRI Fermentas FD0274 
FastDigest KpnI Fermentas FD0274 
FastDigest XhoI Fermentas FD0694 
Proteinase K  
ThermoFisher 
Scientific  
EO0491  
RNase A 10 mg/mL  
ThermoFisher 
Scientific  
EN0531  
T4 DNA Ligase  Invitrogen  15224017 
 
 
5.13  Plasmids 
 
 
 
 
 
Vector name  Company  Cat. No.  
pENTR-shRNA-hTRIP13 (TRCN0000022063)  Sigma-Aldrich  
SHCLND-
NM_004237 
pENTR-shRNA-mTrip13 (TRCN0000319690) Sigma-Aldrich 
SHCLND-
XM_127444  
pGFP-C-shRNA-NTC Origene TL30021 
pGFP-C-shRNA-SIN3A_1  Origene  TL301698A 
pGFP-C-shRNA-SIN3A_4  Origene  TL301698D 
pRFP-CB-shRNA-NTC Origene TL30032 
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pRFP-CB-shRNA-SIN3A_1 Origene  
subcloned 
from Origene 
vector 
pRFP-CB-shRNA-SIN3A_4 Origene 
subcloned 
from Origene 
vector 
psPAX2  Addgene 12260 
pMD2.G  Addgene 12259 
pLKO.1-shRNA-scrambled  Addgene 1864 
pEZX-PG04-HRP-EGFR  Genecopoeia 
HPRM21493-
LvPG04 
 
 
 
5.14  Chemicals 
   
 Product  Company  Cat. No. 
Acetic acid  Sigma-Aldrich  45731 
Agarose  Carl Roth  3810 
Ampicillin sodium salt  Sigma-Aldrich  A9518  
Antifade Mounting Medium with 
DAPI 
Vectashield H-1200 
APS (Ammonium persulfate)  Carl Roth  9592 
β-mercaptoethanol Sigma-Aldrich  M7154  
CaCl2 (Calcium Chloride)  Carl Roth  CN93  
Chloroform (CHCl3)  Carl Roth  3313 
D-Glucose anhydrous  Applichem A0883  
DEPC (Diethylpyrocarbonate)  Sigma-Aldrich  D5758  
DH5α chemically Competent Cells  Invitrogen  18265017 
DTT (Dithiothreitol)  Applichem A2948  
Ethanol, absolute  Sigma-Aldrich  32205 
Formaldehyde solution 37%  Carl Roth  7398,4 
6x DNA Loading Dye  Fermentas  R0611 
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 Product  Company  Cat. No. 
GeneRuler 1 kb Plus DNA Ladder Fermentas  SM1334 
GeneRuler 100 bp Plus DNA Ladder Fermentas  SM0323 
Glycerol  Sigma-Aldrich  15523 
Glycine  Sigma-Aldrich  33226 
H2O2 (Hydrogen peroxide) solution, 
30%  (W/V) in H2O 
Sigma-Aldrich  H1009 
HCl (Hydrochloric acid) 37%  Sigma-Aldrich  30721 
KCl (Potassium chloride)  Carl Roth  A137  
KH2PO4 (Potassium dihydrogen 
phosphate)  
Carl Roth  3904 
LB-Agar (Luria/Miller)  Carl Roth  X969  
LB-Medium (Luria/Miller)  Carl Roth  X968  
Na3VO4 (sodium orthovanadate)  Sigma-Aldrich  S6508  
NaCl (sodium chloride)  Sigma-Aldrich  31434 
NaF (sodium flouride)  Sigma-Aldrich  S1504  
NaOH (sodium hydroxide)  Sigma-Aldrich  30620 
PhosSTOP™ Phosphatase Inhibitor 
tablets 
Roche  
49068450
01 
Ponceau S solution 0.1% in 5% 
acetic acid  
Sigma-Aldrich  P7170  
Precision Plus Protein™ Dual Color 
Standards 
Biorad 1610374 
Protease inhibitor cocktail  Sigma-Aldrich  P8340  
Protease inhibitor cOmplete, EDTA 
free  
Roche  
11873580
001 
Restore Plus Western Blot Striping 
Buffer 
ThermoScientific 46430 
Roti®-Histofix 4% acetic acid free 
(pH 7.0) 
Carl Roth  P087  
S.O.C. Medium  Invitrogen  15544034 
SDS (sodium dodecyl sulfate)  Sigma-Aldrich  D6750  
Skim Milk Powder  Sigma-Aldrich  70166 
Sodium Azide Sigma-Aldrich  S2002 
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 Product  Company  Cat. No. 
Sodium deoxycholate  Sigma-Aldrich  D6750  
Sucrose  Sigma-Aldrich  S1888  
Triton® X-100  Applichem A1388  
TRIzol
™
 Reagent Invitrogen 15596026 
Tween® _20  Sigma-Aldrich  P9416  
16% Formaldehyde (w/v), Methanol-
free 
ThermoScientific 
Pierce 
28908 
 
 
5.15  Cell culture reagents 
   
 Product  Company  Cat. No. 
DMEM High Glucose Pyruvate (+ L-
glutamine)  
Life Technologies
™
Gibco 41966-029  
DMEM Low Glucose Pyruvate (+ L-
glutamine)  
Life Technologies
™ 
Gibco 31885-023  
RPMI 1640 Medium  Life Technologies
™
Gibco 11875093 
DMEM/F-12, HEPES Life Technologies
™ 
Gibco 11330057 
Hoechst 33342, trihydrochloride 
trihydrate, 10 mg/mL  
Life Technologies
™ 
Gibco 
H3570  
Lipofectamine
™
 2000 Transfection 
Reagent 
Invitrogen 11668019 
Lipofectamine
™
 3000 Transfection 
Reagent 
Invitrogen L3000015 
Lipofectamine™ RNAiMAX 
Transfection Reagent 
Invitrogen 13778150 
Opti-MEM® I Reduced Serum 
Medium  
Life Technologies
™ 
Gibco 31985-047  
Polybrene (hexadimethrine bromide)  Sigma-Aldrich   H9268  
Pyruvate 100mM, 100x  Life Technologies
™ 
Gibco 11360-039  
Puromycin  Sigma-Aldrich   P8833  
Blasticidin S HCL 10 mg/mL Life Technologies
™ 
Gibco A1113903 
0.25% Trypsin-EDTA (1x), Phenol 
red  
Life Technologies
™ 
Gibco 25200-056  
DPBS, no CaCl2, no MgCl2  Life Technologies
™ 
Gibco 14190-094  
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 Product  Company  Cat. No. 
Fetal bovine serum (FBS)  Life Technologies
™ 
Gibco 26400-036  
HEPES Buffer solution, 1M  Life Technologies
™ 
Gibco 15630-056  
Penicillin-streptomycin, liquid, 100x  Life Technologies
™ 
Gibco 15140-122  
Tryphan blue solution, 0.4%  Life Technologies
™ 
Gibco T10282  
Water, nuclease free  Life Technologies
™ 
Gibco 10977-035  
BSA for cell culture: Albumin 
solution from bovine serum, 30% 
DPBS, sterile-filtered  
Sigma-Aldrich   A9576  
DMSO (Dimethylsulfoxide) sterile 
for cell culture  
Sigma-Aldrich  D2650  
 
 
 
5.16  Antibodies 
 
 
  
Primary Antibodies   Company  Cat. No.  Origin 
AKT  Cell Signaling  9272 Rabbit  
c-MYC Cell Signaling  9402 Rabbit 
Cleaved Caspase-3  Cell Signaling  9664S  Rabbit  
Cleaved PARP  Cell Signaling  9544S  Mouse  
CyclinD1  Cell Signaling  2926 Mouse  
EGFR Cell Signaling  4267 Rabbit  
phospho-EGFR  Cell Signaling  3777 Rabbit  
HSP90 Abcam  ab13492 Mouse 
Lamin A/C Abcam  ab8984 Mouse 
p53  Cell Signaling  2524S  Mouse  
p70S6K  Cell Signaling  2708 Rabbit  
Phospho-p70S6K  Cell Signaling  9234 Rabbit  
Phospho-AKT  Cell Signaling  9271 Rabbit  
Phospho-Histone H2A.X  Cell Signaling  9718 Rabbit  
phospho-SAPK/JNK 
(Thr183/Tyr185) (G9) 
Cell Signaling 9255 Mouse 
SAP130  Proteintech  12130-1-AP Rabbit 
SAP130  Novusbio NB100-1077 Goat 
SIN3A  Novusbio AF6115-SP Goat 
m-SIN3A 
Santa Cruz 
biotechnology 
sc-994 Rabbit 
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TRIP13  Proteintech 19602-1-AP  Rabbit  
Ubiquitin Sigma-Aldrich U0508 Mouse 
VCP  Abcam  Ab11433 Mouse  
β actin  Sigma  A5441  Mouse  
 
 
Secondary Antibodies  Company  Cat. No.  
Anti-Rabbit IgG-HRP  Bio-Rad 170-6516 
Anti-Mouse IgG-HRP  Bio-Rad 172-1019 
Normal goat IgG isotype control Santa Cruz sc-2028 
Normal Rabbit lgG isotype control Santa Cruz sc-2027 
Alexa Fluor 488 - Phalloidin Invitrogen A12379 
Alexa Fluor 488 donkey anti-Rabbit 
IgG (H+L) 
Invitrogen A21206 
Alexa Fluor 488 donkey anti-goat 
IgG (H+L) 
Invitrogen A11055 
Alexa Fluor 555 donkey anti-Rabbit 
IgG (H+L) 
Invitrogen A-21428 
Alexa Fluor 555 donkey anti-goat 
IgG (H+L) 
Invitrogen A-21432 
 
 
 
5.17  Software 
 
 Product  Company/Source 
Graphpad Prism 6 GraphPad Software 
Illustrator  Adobe system 
ImageJ  https://imagej.nih.gov/ij/ 
ImageLab  Biorad  
Microsoft Office  Microsoft 
ND-1000  Nanodrop  
Photoshop  Adobe System 
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UCSC Genome Browser  http://genome.ucsc.edu 
Papers version 3 Mekentosj B.V 
Primer-Blast 
https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
Olympus Fluoview  Olympus  
 
 
 
5.18  Commercial probes for TaqMan quantitative PCR 
 
 
Gene Species 
Entrez 
Gene ID 
 TaqMan Assay ID  
TRIP13 Human 9319 Hs01020073_m1 
Trip13  Mouse  69716 Mm01352446_m1  
EGFR Human 1956 Hs01076090_m1 
Egfr Mouse  13649 Mm01187858_m1 
SIN3A Human 25942 Hs00411592_m1 
Sin3A Mouse  20466 Mm00488255_m1  
SAP130 Human 79595 Hs01089391_m1 
Sap130 Mouse  269003 Mm00556995_m1  
MYC Human 4609 Hs00153408_m1 
Cyclin D1 Human 595 Hs00765553_m1 
cyclin D1 Mouse  12443 Mm00432359_m1  
TBP Human 6908 Hs00427620_m1 
Tbp Mouse  21374 Mm01277042_m1  
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5.19 Solutions and Buffers  
 
All stock solutions and buffers were prepared in filtered water unless otherwise stated 
  
Blocking Buffer (5% Milk/TBST) 
1x TBS, 0.1% Tween 20, 5% Milk powder  
 
Blocking Buffer (5% BSA/TBST) to block when probing with anti-phosphoantibodies 
1x TBS, 0.1% Tween 20, 5% BSA Fraction V 
 
RIPA Buffer  
50 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 0.5% SDS, 0,1% Sodium deoxycholate  
1 tablet each of PhoSTOP and protease inhibitor is dissolved in 10 ml of RIPA buffer before 
use. 
 
LB agar plate  
40g/L LB agar (Carl Roth) is dissolved in water by warming up the mixture in the 
microwave. Mixture is cooled down before adding appropriate selective antibiotics and 20 ml 
of molten agar was poured per petri dish and allowed to cool down before storing at 4 C for 
up to 1 month 
TBST  
1x TBS with 0.1% Tween 20 
SDS running buffer (10x)  
0.25 M Tris, 1,9 M Glycine, 1% SDS  
 
TBE Buffer (10x)  
100 mM Tris, 1 mM EDTA, 90 mM Boric acid, pH 8.0  
 
TE Buffer  
1 mM EDTS, 10 mM Tris HCl, pH 8.0  
 
Transfer Buffer  
25 mM Tris, 190 mM Glycine, 20% Methanol, 0.1% SDS 
 
10X TBS stock 
500 mM Tris-HCL, PH7.4, 1.5mM Nacl  
 
5X SDS Sample Buffer  
250 mM Tris/HCl pH 6.8, 0.5 M DTT, 10% SDS, 50% glycerol, 0.01% bromophenol blue
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6 Appendices 
S1 Expression profiling of TRIP13 and EGFR in HCC patient cohorts 
from different etiology background 
One of the patient cohorts A_33_P3407256 was disregarded, as there was no 
difference in TRIP13 expression across different HCC etiology. TRIP13 
expression is upregulated across all HCC etiology from the other patient cohort 
of A_33_P3339212. EGFR expression remains constant across all HCC 
etiology groups. No correlation was observed between EGFR and TRIP13 in 
HCC patient cohorts. 
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S2 Gene expression levels between 8 hrs-72 hrs post siRNA 
transfections to knockdown either TRIP13 or SIN3A or both  
RNA samples were harvested at 8, 24, 48 and 72 hrs post siRNA transfections. 
siR KD efficiencies along with expression levels of EGFR, CyclinD1 and c-
MYC were quantified via qPCR analysis. 
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S3 Protein expression levels between 8 hrs-72 hrs post siRNA 
transfections to knockdown either TRIP13 or SIN3A or both  
Cell lysates were harvested at 8, 18, 20, 24 post siRNA transfections. siR KD 
efficiencies along with expression levels of c-MYC were verified via 
immunoblotting for SIN3A, TRIP13 and c-MYC using VCP as a loading 
control 
 
                                                                                        
 
 97 
 
References  
 
1. Ford, E. S., Giles, W. H. & Mokdad, A. H. Increasing prevalence of the metabolic 
syndrome among u.s. Adults. Diabetes Care 27, 2444–2449 (2004). 
2. Calle, E. E., Rodriguez, C., Walker-Thurmond, K. & Thun, M. J. Overweight, 
Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. 
New England Journal of Medicine 348, 1625–1638 (2003).  
3. Nair, S. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? 
Hepatology 36, 150–155 (2002). 
4. Regimbeau, J. M. et al. Obesity and diabetes as a risk factor for hepatocellular 
carcinoma. Liver Transplantation 10, S69–S73 (2004). 
5. Neuschwander-Tetri, B. A. & Caldwell, S. H. Nonalcoholic steatohepatitis: summary 
of an AASLD Single Topic Conference. in 37, 1202–1219 (W.B. Saunders, 2003). 
6. Marchesini, G. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. 
Hepatology 37, 917–923 (2003). 
7. Matteoni, C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and 
pathological severity. YGAST 116, 1413–1419 (1999). 
8. Siegel, A. B. & Zhu, A. X. Metabolic syndrome and hepatocellular carcinoma. Cancer 
115, 5651–5661 (2009). 
9. Solinas, G. & Karin, M. JNK1 and IKKbeta: molecular links between obesity and 
metabolic dysfunction. FASEB J. 24, 2596–2611 (2010). 
10. Park, E. J. et al. Dietary and Genetic Obesity Promote Liver Inflammation and 
Tumourigenesis by Enhancing IL-6 and TNF Expression. Cell 140, 197–208 (2010). 
11. Nawrocki, A. R. & Scherer, P. E. Keynote review: The adipocyte as a drug discovery 
target. Drug Discovery Today 10, 1219–1230 (2005). 
12. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence 
and proposed mechanisms. Nature Reviews Cancer 4, 579–591 (2004). 
13. Ahmed, M. & Gaffen, S. L. IL-17 in obesity and adipogenesis. Cytokine & Growth 
Factor Reviews 21, 449–453 (2010). 
14. Bruun, J. M. Regulation of Interleukin 8 Production and Gene Expression in Human 
Adipose Tissue in Vitro. Journal of Clinical Endocrinology & Metabolism 86, 1267–
1273 (2001). 
15. Schwarzenberg, S. J. & Sinaiko, A. R. Obesity and inflammation in children. Paediatr 
Respir Rev 7, 239–246 (2006). 
16. 16Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. 
Invest. 115, 1111–1119 (2005). 
17. Berg, A. H. & Scherer, P. E. Adipose tissue, inflammation, and cardiovascular disease. 
Circ. Res. 96, 939–949 (2005). 
18. Forner, A. & Bruix, J. Biomarkers for early diagnosis of hepatocellular carcinoma. 
Lancet Oncol. 13, 750–751 (2012). 
19. Luedde, T., Kaplowitz, N. & Schwabe, R. F. Cell Death and Cell Death Responses in 
Liver Disease: Mechanisms and Clinical Relevance. Gastroenterology 147, 765–
783.e4 (2014). 
20. Boege, Y. et al. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-
Associated DNA Damage, a Key Determinant of Liver Cancer Development. Cancer 
Cell 32, 342–359.e10 (2017). 
                                                                                        
 
 98 
21. Ruhl, C. E. & Everhart, J. E. Elevated Serum Alanine Aminotransferase and γ-
Glutamyltransferase and Mortality in the United States Population. Gastroenterology 
136, 477–485.e11 (2009). 
22. McPherson, S., Henderson, E., Burt, A. D., Day, C. P. & Anstee, Q. M. Serum 
immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver 
disease. Journal of Hepatology 60, 1055–1062 (2014). 
23. Hyeon, C. K. et al. Normal serum aminotransferase concentration and risk of mortality 
from liver diseases: prospective cohort study. BMJ 328, 983 (2004). 
24. Hanson, P. I. & Whiteheart, S. W. AAA+ proteins: have engine, will work. Nat. Rev. 
Mol. Cell Biol. 6, 519–529 (2005). 
25. Bhalla, N. & Dernburg, A. F. A conserved checkpoint monitors meiotic chromosome 
synapsis in Caenorhabditis elegans. Science 310, 1683–1686 (2005). 
26. Joyce, E. F. & McKim, K. S. Chromosome Axis Defects Induce a Checkpoint-
Mediated Delay and Interchromosomal Effect on Crossing Over during Drosophila 
Meiosis. PLoS Genet 6, e1001059 (2010). 
27. Zanders, S., Sonntag Brown, M., Chen, C. & Alani, E. Pch2 modulates chromatid 
partner choice during meiotic double-strand break repair in Saccharomyces cerevisiae. 
Genetics 188, 511–521 (2011). 
28. Wang, K. et al. Thyroid Hormone Receptor Interacting Protein 13 (TRIP13) AAA-
ATPase Is a Novel Mitotic Checkpoint-silencing Protein. Journal of Biological 
Chemistry 289, 23928–23937 (2014). 
29. Eytan, E. et al. Disassembly of mitotic checkpoint complexes by the joint action of the 
AAA-ATPase TRIP13 and p31comet. Proceedings of the National Academy of 
Sciences 111, 12019–12024 (2014). 
30. Sudakin, V., Chan, G. K. T. & Yen, T. J. Checkpoint inhibition of the APC/C in HeLa 
cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. The Journal 
of Cell Biology 154, 925–936 (2001). 
31. Mapelli, M., Massimiliano, L., Santaguida, S. & Musacchio, A. The Mad2 
Conformational Dimer: Structure and Implications for the Spindle Assembly 
Checkpoint. Cell 131, 730–743 (2007). 
32. Yang, M. et al. p31comet blocks Mad2 activation through structural mimicry. Cell 
131, 744–755 (2007). 
33. Teichner, A. et al. p31comet Promotes disassembly of the mitotic checkpoint complex 
in an ATP-dependent process. Proc. Natl. Acad. Sci. U.S.A. 108, 3187–3192 (2011). 
34. Ma, H. T. & Poon, R. Y. C. TRIP13 Regulates Both the Activation and Inactivation of 
the Spindle-Assembly Checkpoint. Cell Rep 14, 1086–1099 (2016). 
35. Martin, K. J., Patrick, D. R., Bissell, M. J. & Fournier, M. V. Prognostic breast cancer 
signature identified from 3D culture model accurately predicts clinical outcome across 
independent datasets. PLoS ONE 3, e2994 (2008). 
36. Rhodes, D. R. et al. Large-scale meta-analysis of cancer microarray data identifies 
common transcriptional profiles of neoplastic transformation and progression. 
Proceedings of the National Academy of Sciences 101, 9309–9314 (2004). 
37. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of 
chromosomal instability inferred from gene expression profiles predicts clinical 
outcome in multiple human cancers. Nat Genet 38, 1043–1048 (2006). 
38. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human cancers. 
Nature 396, 643–649 (1998). 
39. Weiler, S. M. E. et al. Induction of Chromosome Instability by Activation of Yes-
Associated Protein and Forkhead Box M1 in Liver Cancer. Gastroenterology 152, 
2037–2051.e22 (2017). 
                                                                                        
 
 99 
40. Wilkens, L. et al. Induction of aneuploidy by increasing chromosomal instability 
during dedifferentiation of hepatocellular carcinoma. Proceedings of the National 
Academy of Sciences 101, 1309–1314 (2004). 
41. Plentz, R. R. et al. Hepatocellular telomere shortening correlates with chromosomal 
instability and the development of human hepatoma. Hepatology 40, 80–86 (2004). 
42. Yimlamai, D., Fowl, B. H. & Camargo, F. D. Emerging evidence on the role of the 
39/YAP pathway in liver physiology and cancer. Journal of Hepatology 63, 1491–
1501 (2015). 
43. Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. & Kim, J. M. Gain at chromosomal 
region 5p15.33, containing TERT, is the most frequent genetic event in early stages of 
non-small cell lung cancer. Cancer Genetics and Cytogenetics 182, 1–11 (2008). 
44. Tipton, A. R. et al. Identification of novel mitosis regulators through data mining with 
human centromere/kinetochore proteins as group queries. BMC Cell Biol. 13, 15 
(2012). 
45. Banerjee, R. et al. TRIP13 promotes error-prone nonhomologous end joining and 
induces chemoresistance in head and neck cancer. Nature Communications 5, 1–16 
(1AD). 
46. Silverstein, R. A. & Ekwall, K. Sin3: a flexible regulator of global gene expression 
and genome stability. Current Genetics 47, 1–17 (2004). 
47. Nasmyth, K. Both positive and negative regulators of HO transcription are required for 
mother-cell-specific mating-type switching in yeast. Cell 48, 579–587 (1987). 
48. Kadamb, R., Mittal, S., Bansal, N., Batra, H. & Saluja, D. Sin3: Insight into its 
transcription regulatory functions. European Journal of Cell Biology 92, 237–246 
(2013). 
49. Bansal, N., David, G., Farias, E. & Waxman, S. Emerging Roles of Epigenetic 
Regulator Sin3 in Cancer. Advances in Cancer Research 130, 113–135 (Elsevier Inc., 
2016). 
50. Grzenda, A., Lomberk, G., Zhang, J.-S. & Urrutia, R. Sin3: Master scaffold and 
transcriptional corepressor. Biochimica et Biophysica Acta (BBA) - Gene Regulatory 
Mechanisms 1789, 443–450 (2009). 
51. Baymaz, H. I., Karemaker, I. D. & Vermeulen, M. Perspective on unraveling the 
versatility of ‘co-repressor’ complexes. Biochimica et Biophysica Acta (BBA) - Gene 
Regulatory Mechanisms 1849, 1051–1056 (2015). 
52. Baltus, G. A., Kowalski, M. P., Tutter, A. V. & Kadam, S. A positive regulatory role 
for the mSin3A-HDAC complex in pluripotency through Nanog and Sox2. Journal of 
Biological Chemistry 284, 6998–7006 (2009). 
53. Garcia-Sanz, P. et al. Sin3b Interacts with Myc and Decreases Myc Levels. Journal of 
Biological Chemistry 289, 22221–22236 (2014). 
54. Dannenberg, J.-H. et al. mSin3A corepressor regulates diverse transcriptional 
networks governing normal and neoplastic growth and survival. Genes Dev. 19, 1581–
1595 (2005). 
55. Cultraro, C. M., Bino, T. & Segal, S. Function of the c-Myc antagonist Mad1 during a 
molecular switch from proliferation to differentiation. Molecular and Cellular Biology 
17, 2353–2359 (1997). 
56. Das, T. K., Sangodkar, J., Negre, N., Narla, G. & Cagan, R. L. Sin3a acts through a 
multi-gene module to regulate invasion in Drosophila and human tumours. Oncogene 
32, 3184–3197 (2013). 
57. Hudis, C. A. & Gianni, L. Triple-negative breast cancer: an unmet medical need. 
Oncologist 16 Suppl 1, 1–11 (2011). 
                                                                                        
 
 100 
58. André, F. & Zielinski, C. C. Optimal strategies for the treatment of metastatic triple-
negative breast cancer with currently approved agents. Ann. Oncol. 23 Suppl 6, vi46–
51 (2012). 
59. Bansal, N. et al. Targeting the SIN3A-PF1 interaction inhibits epithelial to 
mesenchymal transition and maintenance of a stem cell phenotype in triple negative 
breast cancer. Oncotarget 6, (2015). 
60. Kwon, Y.-J. et al. Selective Inhibition of SIN3 Corepressor with Avermectins as a 
Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Mol. Cancer Ther. 14, 
1824–1836 (2015). 
61. Farias, E. F. et al. Interference with Sin3 function induces epigenetic reprogramming 
and differentiation in breast cancer cells. Proceedings of the National Academy of 
Sciences 107, 11811–11816 (2010). 
62. Yu, J., Shen, J., Sun, T. T., Zhang, X. & Wong, N. Obesity, insulin resistance, NASH 
and hepatocellular carcinoma. Semin. Cancer Biol. 23, 483–491 (2013). 
63. Ye, Q. et al. TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 
conformation switching. eLife 4, 213 (2015). 
64. Ferlay, J. et al. Cancer incidence and mortality worldwide: Sources, methods and 
major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015). 
65. Yang, J. D. & Roberts, L. R. Hepatocellular carcinoma: a global view. Nature Reviews 
Gastroenterology &Amp; Hepatology 7, 448 EP ––1341.e23 (2017). 
66. Zucman-Rossi, J., Villanueva, A., Nault, J-C. & Llovet, J. M. Genetic Landscape and 
Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149, 1226–1239.e4 
(2015). 
67. Nahon, P. & Zucman-Rossi, J. Single nucleotide polymorphisms and risk of 
hepatocellular carcinoma in cirrhosis. Journal of Hepatology 57, 663–674 (2012). 
68. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic 
fatty liver disease. Nat Genet 40, 1461–1465 (2008). 
69. Singal, A. G. et al. The Effect of PNPLA3 on Fibrosis Progression and Development 
of Hepatocellular Carcinoma: A Meta-analysis. The American Journal of 
Gastroenterology 109, 325–334 (2014). 
70. Nault, J.-C. et al. High frequency of telomerase reverse-transcriptase promoter somatic 
mutations in hepatocellular carcinoma and preneoplastic lesions. Nature 
Communications 4, 1245 (2013). 
71. Hartmann, D. et al. Telomerase gene mutations are associated with cirrhosis 
formation. Hepatology 53, 1608–1617 (2011). 
72. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719–
724 (2009). 
73. La Coste, de, A. et al. Somatic mutations of the beta-catenin gene are frequent in 
mouse and human hepatocellular carcinomas. Proceedings of the National Academy of 
Sciences 95, 8847–8851 (1998). 
74. Hsu, I. C. et al. Mutational hotspot in the p53 gene in human hepatocellular 
carcinomas. Nature 350, 427–428 (1991). 
75. Satoh, S. et al. AXIN1 mutations in hepatocellular carcinomas, and growth 
suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 24, 245–
250 (2000). 
76. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological 
influences on mutation patterns and recurrent mutations in chromatin regulators. Nat 
Genet 44, 760–764 (2012). 
77. Li, M. et al. Inactivating mutations of the chromatin-remodeling gene ARID2 in 
hepatocellular carcinoma. Nat Genet 43, 828–829 (2011). 
                                                                                        
 
 101 
78. Sporn, M. B. & Liby, K. T. NRF2 and cancer: the good, the bad and the importance of 
context. Nature Reviews Cancer 12, 564–571 (2012). 
79. Villanueva, A. et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. 
Gastroenterology 135, 1972–83– 1983.e1–11 (2008). 
80. Law, P. T.-Y. et al. Deep sequencing of small RNA transcriptome reveals novel non-
coding RNAs in hepatocellular carcinoma. Journal of Hepatology 58, 1165–1173 
(2013). 
81. Vader, G. Pch2TRIP13: controlling cell division through regulation of HORMA 
domains. Chromosoma 124, 333–339 (2015). 
82. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 
359, 378–390 (2008). 
83. Abdel-Rahman, O. Impact of baseline characteristics on outcomes of advanced HCC 
patients treated with sorafenib: a secondary analysis of a phase III study. J. Cancer 
Res. Clin. Oncol. 11, 183 (2018). 
84. Zhou, K. et al. Loss of thyroid hormone receptor interactor 13 inhibits cell 
proliferation and survival in human chronic lymphocytic leukemia. Oncotarget 8, 
25469–25481 (2017). 
85. Lee J. W.et al. Two classes of proteins dependent on either the presence or absence of 
thyroid hormone for interaction with the thyroid hormone receptor. Molecular 
endocrinology 9, 243–254 (1995). 
86. Yasugi T.et al. Two classes of human papillomavirus type 16 E1 mutants suggest 
pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, 
and interaction with cellular proteins. Journal of virology 71, 5942–5951 (1997) 
87. Roig I. et al. Mouse TRIP13/PCH2 is required for recombination and normal higher-
order chromosome structure during meiosis. PLoS genetics 6, 1001062 (2010) 
88. Pressly, J. D. et al. TRIP13-deficient tubular epithelial cells are susceptible to 
apoptosis following acute kidney injury. Science Report 1–13, (2017) 
89. Marinkovic, D. et al Identification of novel Myc target genes with a potential role in 
lymphomagenesis. Nucleic Acids Research 32, 5368–5378 (2004). 
90. Wanzel, M., Herold, S. & Eilers, M. Transcriptional repression by Myc. Trends Cell 
Biol. 13, 146–150 (2003). 
91. Tu, W. B. et al. Myc and its interactors take shape. Biochim. Biophys. Acta 1849, 469–
483 (2015). 
92. Nascimento, E. M. et al. The opposing transcriptional functions of Sin3a and c-Myc 
are required to maintain tissue homeostasis. Nat Cell Biol 13, 1395–1405 (2011). 
93. Natarajan A, et al. The EGF receptor is required for efficient liver regeneration. Proc 
Natl Acad Sci USA 104:17081- 1708 (2014) 
94. Lanaya H, Natarajan A, Komposch K, et al.  EGFR has a tumour-promoting role in 
liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 16, 972-
981 (2014). 
95. Lopez-Luque J, Caballero-Diaz D, Martinez-Palacian A, et al. Dissecting the role of 
the epidermal growth factor receptor catalytic activity during liver regeneration and 
hepatocarcinogenesis. HEPATOLOGY 63, 604-619  (2016) 
96. Berasain, C. & Avila, M. A. Further evidence on the janus-faced nature of the 
epidermal growth factor receptor: From liver regeneration to hepatocarcinogenesis. 
Hepatology 63, 371–374 (2016). 
97. Whitfield, J. R. & Soucek, L. Tumour microenvironment: becoming sick of Myc. Cell. 
Mol. Life Sci. 69, 931–934 (2012). 
98. Meyer, N. & Penn, L. Z. Reflecting on 25 years with MYC. Nature Reviews Cancer 8, 
976–990 (2008). 
                                                                                        
 
 102 
99. Miller, D. M., et al. c-Myc and Cancer Metabolism. Clinical Cancer Research 18, 
5546–5553 (2012). 
100. Zheng, K., Cubero, F. J. & Nevzorova, Y. A. c-MYC-Making Liver Sick: Role of c-
MYC in Hepatic Cell Function, Homeostasis and Disease. Genes (Basel) 8, 123 
(2017). 
101. Dauch, D. et al. A MYC-aurora kinase A protein complex represents an actionable 
drug target in p53-altered liver cancer. Nat. Med. 22, 744–753 (2016). 
102. Kira, S. et al. Expression of transforming growth factor alpha and epidermal growth 
factor receptor in human hepatocellular carcinoma. Liver 17, 177–182 (2008). 
103. Bejarano, P. A. Epidermal Growth Factor Receptor Expression and Gene Copy 
Number in Conventional Hepatocellular Carcinoma. Yearbook of Pathology and 
Laboratory Medicine 2010, 42 (2010). 
104. Harada, K.-I., Shiota, G. & Kawasaki, H. Transforming growth factor-a and epidermal 
growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 
International 19, 318–325 (1999). 
105. Baselga, J. & Arteaga, C. L. Critical Update and Emerging Trends in Epidermal 
Growth Factor Receptor Targeting in Cancer. Journal of Clinical Oncology 23, 2445–
2459 (2005). 
106. Marshall, J. Clinical implications of the mechanism of epidermal growth factor 
receptor inhibitors. Cancer 107, 1207–1218 (2006). 
107. Höpfner, M. et al. Targeting the epidermal growth factor receptor by gefitinib for 
treatment of hepatocellular carcinoma. Journal of Hepatology 41, 1008–1016 (2004). 
108. Shachaf, C. M. et al. MYC inactivation uncovers pluripotent differentiation and 
tumour dormancy in hepatocellular cancer. Nature 431, 1112–1117 (2004). 
109. Beer, S. et al. Hepatotoxin-Induced Changes in the Adult Murine Liver Promote 
MYC-Induced Tumourigenesis. PLoS ONE 3, e2493 (2008). 
110. Anderson, D. J. et al. Targeting the AAA ATPase p97 as an Approach to Treat Cancer 
through Disruption of Protein Homeostasis. Cancer Cell 28, 653–665 (2015). 
111. Tong Zhou, Jeff Chou. et al.  (2007) Identification of Primary Transcriptional 
Regulation of Cell Cycle-Regulated Genes upon DNA Damage, Cell Cycle, 6:8, 972-
981 (2007) 
112. Van der Meijden CM, Lapointe DS, Luong MX, et al. Gene profiling of cell cycle 
progression through S-phase reveals sequential expression of genes required for DNA 
replication and nucleosome assembly. Cancer Res 62, 3233-43 (2002) 
113. Ren B, Cam H, Takahashi Y, et al. E2F integrates cell cycle progression with DNA 
repair, replication, and G (2)/M checkpoints. Genes Dev. 16 245-56 (2002) 
114. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal 
protein haploinsufficiency. Nature 456, 971-5 (2008) 
115. Berasain, C. & Avila, M. A. The EGFR signalling system in the liver: from 
hepatoprotection to hepatocarcinogenesis. J. Gastroenterol. 49, 9–23 (2014). 
116. Buckley, A. F., Burgart, L. J., Sahai, V. & Kakar, S. Epidermal Growth Factor 
Receptor Expression and Gene Copy Number in Conventional Hepatocellular 
Carcinoma. American Journal of Clinical Pathology 129, 245–251 (2008)
 
 
 
 
 
 
 
